



(11) EP 1 740 951 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
05.03.2008 Bulletin 2008/10

(51) Int Cl.:
G01N 33/553 (2006.01) G01N 33/543 (2006.01)
G01N 33/58 (2006.01)

(21) Application number: 04730243.5

(86) International application number:
PCT/EP2004/004547

(22) Date of filing: 29.04.2004

(87) International publication number:
WO 2005/111619 (24.11.2005 Gazette 2005/47)

(54) METHOD AND KIT FOR DETECTING COMPONENTS IN A SAMPLE

VERFAHREN UND KIT ZUM NACHWEIS VON BESTANDTEILEN IN EINER PROBE

PROCEDE ET KIT POUR DETECTER DES COMPOSANTS DANS UN ECHANTILLON

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(56) References cited:
US-A- 5 691 207 US-A1- 2002 000 398
US-A1- 2003 186 274

(43) Date of publication of application:
10.01.2007 Bulletin 2007/02

- DANKNER W M ET AL: "DETECTION OF HUMAN CYTOMEGALOVIRUS BY IMMUNOGOLD AND SILVER ENHANCEMENT" JOURNAL OF HISTOTECHNOLOGY, vol. 12, no. 1, 1989, pages 9-13, XP008039826 ISSN: 0147-8885
- SKUTELSKY E ET AL: "THE USE OF AVIDIN-GOLD COMPLEX FOR LIGHT MICROSCOPIC LOCALIZATION OF LECTIN RECEPTORS" HISTOCHEMISTRY, vol. 86, no. 3, 1987, pages 291-296, XP008039829 ISSN: 0301-5564
- BRONCKERS A L ET AL: "Immunolocalization of Gla proteins (osteocalcin) in rat tooth germs: comparison between indirect immunofluorescence, peroxidase-antiperoxidase, avidin-biotin-peroxidase complex, and avidin-biotin-gold complex with silver enhancement." THE JOURNAL OF HISTOCHEMISTRY AND CYTOCHEMISTRY : OFFICIAL JOURNAL OF THE HISTOCHEMISTRY SOCIETY. AUG 1987, vol. 35, no. 8, August 1987 (1987-08), pages 825-830, XP008039833 ISSN: 0022-1554

(73) Proprietor: Ramael, Marc
9120 Haasdonk (BE)

(72) Inventor: Ramael, Marc
9120 Haasdonk (BE)

(74) Representative: Brants, Johan P.E. et al
De Clercq Brants & Partners
Edgard Gevaertdreef 10a
9830 Sint-Martens-Latem (BE)

EP 1 740 951 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**BACKGROUND TO THE INVENTION**

5 [0001] Micro-arrays are tools for protein, DNA and RNA molecular diagnostics, often used for the detection of nucleic acids and proteins. Such parallelisation techniques, enable the investigation of several thousands of sequences in one reaction or experiment. Most applications are focused on expression profiling for measuring adequately the expression of several thousands genes of interest. Presently, detection of molecular binding on micro-arrays is effected by use of special fluorescent dyes such as Cy3 and Cy5. However, the accuracy and reproducibility of such techniques is limited
10 by the stability of the fluorescent marker.

[0002] Sequence-selective DNA detection has become increasingly important as scientists unravel the genetic basis of disease and use this new information to improve medical diagnosis and treatment. DNA hybridization tests on oligonucleotide-modified substrates are commonly used to detect the presence of specific DNA sequences in solution. The developing promise of combinatorial DNA arrays for probing genetic information illustrates the importance of these
15 heterogeneous sequence assays to future science. In most assays, the hybridization of fluorophore-labeled targets to surface bound probes is monitored by fluorescence microscopy or densitometry. Although fluorescence detection is very sensitive, its use is limited by the expense of the experimental equipment and by background emissions from most common substrates. In addition, the selectivity of labeled oligonucleotide targets for perfectly complementary probes over those with single base mismatches is poor, preventing the use of surface hybridization tests for detection of single
20 nucleotide polymorphisms. Another disadvantage is that the evaluation of processed fluorescence based micro-arrays needs highly expensive laser scanning devices, as well as highly sophisticated software for analysing the data generated by the laser scanning devices. Such equipment is not available to all laboratories, and certainly not to laboratories with limited resources. Thus a major drawback of this technology is the capital expense, and its use restricted to well resourced laboratories.

25 [0003] A limited number of prior art documents describe detection methods and/or reagents for use in solid-phase assays, but each is associated with numerous disadvantages. Enzymatic methods or gold-based detection method on micro-arrays are described in WO 00/72018, EP 1164201, EP 1096024, WO 01177372A2, US 2001/0010906A1. The patent application number WO 0017201 describes the use of biotinylated DNA on micro-array using streptavidin labelled gold. Other patent documents such as EP 1164201, EP 1096024 and WO 01/77372A2 describe methods and kits for
30 detection and quantification of homologue nucleotides, method and kit for diagnosis and quantification using sandwich hybridisation on solid carrier (US 2001/0010906A1). Patent document EP 1164201 describes the use of inverted detection for identifying and/or quantifying nucleotide target sequences on biochips using micro-fluidity techniques. Patent document EP 10960245 describes a method for detection of homologue sequences after multiplex PCR for detecting *Staphylococcus* microorganisms. Patent documents AU8366001, AU7547501, CA2397280, WO 01/96604 and WO
35 99/20789 describe a detection technique using streptavidin labelled gold particles of at least 80 nm for visualisation of bound nucleic acids on micro-array. Patent document US 6451980 describes a technique for signal enhancement using a bi-specific antibody-polymer probe, wherein one part of said probe recognises the antigen and the other part is directed against DTPA (diethylenepentaacetic acid). Patent document WO 02106511 (Genisphere) describes an amplification technique applicable to micro-arrays using a DNA dendrimer-based approach. Patent document WO 01/36681 (Digene)
40 discloses a technology for detecting DNA/RNA hybrids on micro-arrays using a monoclonal antibody directed specifically to RNA/DNA hybrids with visualisation using fluorescent dyes. Patent document WO 96/14314 (DAKO) describes the use of a specific monoclonal antibody for detecting DNA/PNA nucleic acid hybrids. The use of lectins or dextran coated with biotin molecules for use specially in *in situ* hybridization is disclosed in patent document EP0151492 (ENZO).

[0004] US 5,691,207 describes a method of assaying a sample for the presence of an analyte involving immobilization
45 of gold sol and optionally an enzyme capable of generating a reaction product on a solid phase. W.M. Danker et al The Journal of Histotechnology, 1989, Vol 12(1), pages 9-13 describes a comparison of immunocytochemistry kits which use avidin-biotin complex, indirect immunogold silver enhancement, or streptavidin 5nm gold sol. US 2003/0186274 describes a method for detecting or quantifying a biological substance coupled with a colloidal metal particle by electrochemical detection, using a step of dissolving by chemical treatment said colloidal metal particle prior to detection.
50 US 2002/0000398 describes a method for separating materials using colloidal, magnetizable aggregates coated with one or more layers of novel polysaccharide derivatives.

[0005] A detection scheme which improves upon the simplicity, sensitivity and selectivity of methods in the art could allow the full potential of combinatorial sequence analysis to be realized. Therefore, for reading and analysing arrays at a low cost, with high sensitivity and reproducibility, there is a need for a technique which overcomes the problems of the art.
55 [0006] For generalizing the use of this technology, it would be advantageous to have a visualization technique that enables the investigator to evaluate the hybridization results with the naked eye without use of laser scanning devices or other kind of expensive visualization equipment. Alternatively, a system which enables the use of low cost readers e.g. those which detect electrical conductance and/or changes in magnetic flux would help sensitive array-type assaying

become more cost effective as a research and diagnostic tool.

SUMMARY OF THE INVENTION

5 [0007] One embodiment of the present invention is a method for quantitatively and/or qualitatively detecting one or more components in a sample, each component capable of binding to a probe, comprising steps in the following order:

(a) applying one or more samples onto a solid support,
10 (b) contacting solid support with one or more biotin-labeled probes,
(c) contacting solid support with streptavidin-metal particle complex,
(d) contacting solid support with conjugate comprising:
15 - one or more biotins,
- one or more polymers, and
- metal particles bound to said polymer,
(e) optionally contacting the solid support with metal enhancement reagent, and
(f) reading the solid support to quantitatively and/or qualitatively detect said component.

20 [0008] Another embodiment of the present invention is a method as described above wherein step (a) is replaced by:
(a) applying one or more probes onto solid support,
and step (b) is replaced by:
(b) contacting solid support with biotin-labelled sample.

25 [0009] Another embodiment of the present invention is a method as described above wherein step (a) is preceded by:
(a0) applying one or more probes onto solid support.

30 [0010] Another embodiment of the present invention is a method as described above wherein the solid support is supplied with probe pre-applied, and step (a) of the second embodiment above or step (a0) of the third embodiment above is not performed by the user.

[0011] Another embodiment of the present invention is a method as described above wherein the reading of step (f) comprises the use of a colour chart.

35 [0012] Another embodiment of the present invention is a method as described above wherein the reading of step (f) comprises a use of a device suitable for detecting changes in conductance and/or current across the solid support.

[0013] Another embodiment of the present invention is a method as described above wherein the reading of step (f) comprises a use of a device suitable for detecting changes in magnetic field on the solid support.

[0014] Another embodiment of the present invention is a method as described above wherein the reading of step (f) 40 comprises a use of a device suitable for detecting changes in surface plasmon resonance on the solid support.

[0015] Another embodiment of the present invention is a method as described above wherein the metal enhancement reagent of step (e) is a silver enhancement reagent.

[0016] Another embodiment of the present Invention is a kit for quantitatively and/or qualitatively detecting one or 45 more components in a sample, each component capable of binding to a probe, comprising:
- streptavidin-metal particle complex, and
- solid support, and
conjugate comprising:
50 - biotin,
- polymer, and
- metal particles bound to said polymer,
55 [0017] Another embodiment of the present invention is a kit as described above further comprising one or more probes.
[0018] Another embodiment of the present invention is a kit as described above wherein said probes are biotinylated.
[0019] Another embodiment of the present invention is a kit as described above wherein said solid support preloaded with one or more probes.

[0020] Another embodiment of the present invention is a method or a kit as described above wherein the polymer of a conjugate is a biologically inert polymer, capable of binding to one or more metal particles.

[0021] Another embodiment of the present invention is a method or a kit as described above wherein a polymer is any of albumin or dextran.

5 [0022] Another embodiment of the present invention is a method or a kit as described above wherein conjugate comprises are one or more particles of gold, silver, iron, nickel, gadolinium, lead, uranium, caesium, platinum, rhodium, technetium, tellurium, selenium, silicon, silicium, copper, tin, rhenium, europium, aluminium, germanium, chromium, cadmium, niobium, titanium, magnesium, manganese, molybdenum, antimony, americium, lithium, and/or wolfram.

10 [0023] Another embodiment of the present invention is a method or a kit as described above wherein conjugate comprises one or more gold particles.

[0024] Another embodiment of the present invention is a method or a kit as described above wherein a conjugate comprises one or more silver particles.

[0025] Another embodiment of the present invention is a method or a kit as described above wherein the metal particles of conjugate have a diameter between 0.6 to 40 nm.

15 [0026] Another embodiment of the present invention is a kit as described above for use in a method as described above.

[0027] A method for enhancing the imaging of one or more components in a system by magnetic resonance imaging, each component capable of binding to a probe, may comprise the steps of:

- 20 (i) adding one or more biotin-labelled probes to a system,
- (ii) adding streptavidin-metal particle complex to said system, and
- (iii) obtaining an image using magnetic resonance imaging.

[0028] Another embodiment of the present invention is a kit for enhancing the imaging of one or more components in a system by magnetic resonance imaging, each component being capable of binding to a probe, comprising streptavidin-metal particle complex.

25 [0029] Another embodiment of the present invention is a kit as described above further comprising one or more biotin-labelled probes.

[0030] A kit as described above may be used in a method of enhancing the imaging of one or more components in a system as described above.

30 [0031] Another embodiment of the present invention is a method or a kit as described above wherein said probe is an antibody, nucleic acid, peptide nucleic acid, polypeptide or peptide ligand.

[0032] Another embodiment of the present invention is a method or a kit as described above wherein streptavidin-metal particle complex comprises one or more particles of gold, silver, iron, nickel, gadolinium, lead, uranium, caesium, platinum, palladium, rhodium, technetium, tellurium, selenium, silicon (silicium), copper, tin, rhenium, europium, aluminium, germanium, chromium, cadmium, niobium, titanium, magnesium, manganese, molybdenum, antimony, americium, lithium, and/or wolfram.

[0033] Another embodiment of the present invention is a method or a kit as described above wherein streptavidin-metal particle complex comprises one or more gold particles.

40 [0034] Another embodiment of the present invention is a method or a kit as described above wherein streptavidin-metal particle complex comprises one or more silver particles.

[0035] Another embodiment of the present invention is a method or a kit as described above wherein the metal particles of streptavidin-metal particle complex have a diameter between 0.6 to 40 nm.

[0036] Another embodiment of the present invention is a method or a kit as described above wherein said streptavidin-metal particle complex comprises streptavidin and/or avidin.

45 [0037] Another embodiment of the present invention is a method or a kit as described above wherein the streptavidin-metal particle complex and/or conjugate comprise one or more superparamagnetic particles.

[0038] Another embodiment of the present invention is a method or a kit as described above wherein the streptavidin-metal particle complex comprises one or more superparamagnetic particles, and wherein steps (d) and (e) are not performed.

50 [0039] Another embodiment of the present invention is a method or a kit as described above wherein said superparamagnetic particles comprise iron oxide.

[0040] Another embodiment of the present invention is a method or a kit as described above wherein the iron oxide content of a superparamagnetic particle is between 30 and 80%.

[0041] Another embodiment of the present invention is a method or a kit as described above wherein said superparamagnetic particles have a diameter between 50 and 400nm.

[0042] Another embodiment of the present invention is a method or a kit as described above wherein at least one probe is capable of binding to Human Papillomavirus.

[0043] Another embodiment of the present invention is a method or a kit as described above wherein said probe is

capable of binding to Human Papillomavirus coat polypeptide.

[0044] Another embodiment of the present invention is a method or a kit as described above for detecting, diagnosing and/or monitoring the progress of a Human Papillomavirus (HPV) infection.

5 [0045] Another embodiment of the present invention is a method or a kit as described above wherein at least one probe is capable of binding to a gene selected from the group consisting of HPV 16, HPV18, HPV 31, HPV 33, HPV 35, HPV 52 and HPV 58.

[0046] Another embodiment of the present invention is a method or a kit as described above wherein said probe is capable of binding to a component listed in Table 1.

10 [0047] Another embodiment of the present invention is a method or a kit as described above for detecting, diagnosing and/or monitoring the progress of or susceptibility to one or more of the disease states in humans as listed in Table 1, by detecting a polypeptide and/or nucleic acid corresponding to a component therein.

[0048] Another embodiment of the present invention is a method or a kit as described above wherein at least one probe is capable of binding to any of HCV, HIV, HBV, HTLV, mycobacteria, or *Staphylococcus aureus*.

15 [0049] Another embodiment of the present invention is a method or a kit as described above for detecting, diagnosing and/or monitoring the progress infections caused by one or more of one or more of HCV, HIV, HBV, HTLV, mycobacteria, or *Staphylococcus aureus*.

[0050] Another embodiment of the present invention is a method or a kit as described above wherein at least one probe is capable of binding to one or more of beta-amyloids, hTAU, phosphoTAU and APOE

20 [0051] Another embodiment of the present invention is a method or a kit as described above for use in detecting, diagnosing and/or monitoring the progress neurodegenerative diseases.

[0052] Another embodiment of the present invention is a method or a kit as described above wherein at least one probe is capable of binding to one or more of ANA, Jo-1, Myeloperoxidase, RNP, Scl-70, Sm, SS-A, IgE, IgG-subclasses and circulating antibodies.

25 [0053] Another embodiment of the present invention is a method or a kit as described above for use in detecting, diagnosing and/or monitoring the progress of malignant diseases, autoimmunity or allergy related diseases.

[0054] Another embodiment of the present invention is a method or a kit as described above wherein at least one probe is capable of binding to microorganism contaminants of drinking water.

[0055] Another embodiment of the present invention is a method or a kit as described above for environmental testing of water for bacteria.

30 [0056] Another embodiment of the present invention is a method or a kit as described above for use in environmental testing of food components for genetically modified components, listeria and salmonella.

[0057] Another embodiment of the present invention is a method for staining components in cell and/or tissue sections, said staining suitable for visualisation using microscopy comprises the following steps:

35 A) incubating section with one or more biotinylated probes directed against said components,

B) incubating section with streptavidin-metal particle complex,

C) incubating section with conjugate comprising:

- one or more biotins,

- one or more polymers, and

- metal particles bound to said polymer, and

D) optionally incubating the section with metal enhancement reagent.

45 DETAILED DESCRIPTION OF THE INVENTION

[0058] The present invention relates to methods and reagents for use in the detection of a component in a sample on a solid support, comprising the use of a conjugate comprising biotin, polymer and metal particles of diameter in the nanometer range (i.e. between 0.1 and 500 nm) bound to said polymer. It further relates to reagents for use in enhancing *in vivo* imaging and methods for microscopy. It further relates to diagnostic kits.

50 [0059] In one aspect of the invention, one or more samples are immobilized onto the solid support, one or more probes applied thereto and the binding is detected. Thus, one embodiment of the present invention is a method for quantitatively and/or qualitatively detecting one or more components in a sample, each component capable of binding to a probe, comprising steps in the following order:

55 (a) applying one or more samples onto a solid support,
(b) contacting the solid support with one or more biotin-labeled probes,
(c) contacting the solid support with streptavidin-metal particle complex,

(d) contacting the solid support with conjugate comprising:

- one or more biotins,
- one or more polymers, and
- metal particles bound to said polymer,

(e) optionally contacting the solid support with metal enhancement reagent, and

(f) reading the solid support to quantitatively and/or qualitatively detect said component.

10 [0060] The inventors have found that when the signal of a specific interaction between probe and component is amplified using streptavidin-metal particle complex and the conjugate according to the invention, a sensitive and reproducible qualitative and/or quantitative indication of components is indicated.

[0061] According to one embodiment of the invention, step (a) above is preceded by the application of probe to the solid support. *i.e.*

15 (a0) applying one or more probes onto solid support,
(a) contacting solid support with one or more samples,
(b) contacting solid support with one or more biotin-labeled probes,
(c) contacting solid support with streptavidin-metal particle complex,
20 (d) contacting solid support with conjugate comprising:

- one or more biotins,
- one or more polymers, and
- metal particles bound to said polymer,

25 (e) optionally contacting solid support with metal enhancement reagent, and

(f) reading the solid support to quantitatively and/or qualitatively detect said component.

30 [0062] By applying probe to the solid support prior to the application of sample, sample is selectively bound to the solid support prior to the subsequent step, leading to reduced background signal. The probe of step (b) may be less selective than the probe of step (a0) and still provide a superior signal to noise ratio. The probe of step (a0) may be the same or different from the probe of step (b). For example, the probe of step (a0) may be a monoclonal antibody and the probe of step (b) may be a polyclonal antibody.

35 [0063] In another aspect of the invention, one or more probes are immobilized onto the solid support and one or more samples applied thereto. Thus, another embodiment of the present invention is a method for quantitatively and/or qualitatively detecting one or more components in a sample, each component capable of binding to a probe, comprising steps in the following order:

40 (a) applying one or more probes onto solid support,
(b) contacting solid support with one or more biotin-labelled samples,
(c) contacting the solid support with streptavidin-metal particle complex,
(d) contacting the solid support with conjugate comprising:

- one or more biotins,
- one or more polymers, and
- metal particles bound to said polymer,

45 (e) optionally contacting the solid support with metal enhancement reagent, and

(f) reading the solid support to quantitatively and/or qualitatively detect said component.

50 [0064] By "applying" as used herein in reference to applying one or more samples or probes to a solid support, is meant deposition of one or more synthetic or biological substances on a solid support. The deposition may be by a manual method or by using a device, resulting in an action including, but not limited to spotting, pipetting, printing, jet printing, dropping etc.

55 [0065] The inventors have found that the nanometer scale and sometimes sub-nanometer scale of metal particle used in the streptavidin-metal particle complex and conjugate allows extremely high labelling indices. This provides enhanced detection sensitivity. Furthermore, a method according to the invention requires a minimum two contact steps, (c) and (d), so greatly reducing the time, the number of required reagents, and the possibility for error. The resulting change in

colour not only permits evaluation with a scanning device but also with the naked eye, so obviating the need for optical or electronic detecting devices.

[0066] Furthermore, the inventors have found that using nano-sized particles of metal according to the invention produces a variety of confinement effects which dramatically change the properties of the metal. Such properties appear

5 to be altered when the entity or mechanism responsible for that property is confined within a space smaller than the critical length associated with that entity or mechanism. Some illustrations of such properties include but are not limited to electrical conductivity, dielectric constant, dielectric strength, dielectric loss, polarization, permittivity, critical current, superconductivity, piezoelectricity, mean free path, curie temperature, critical magnetic field, permeability, coercive force, magnetostriction, magnetoresistance, hall coefficient, BHmax, critical temperature, melting point, boiling point, sublimation point, phase transformation conditions, vapor pressure, anisotropy, adhesion, density, hardness, ductility, elasticity, porosity, strength, toughness, surface roughness, coefficient of thermal expansion, thermal conductivity, specific heat, latent heat, refractive index, absorptivity, emissivity, dispersivity, scattering, polarization, acidity, basicity, catalysis, reactivity, energy density, activation energy, free energy, entropy, frequency factor, environmental benigness, bioactivity, biocompatibility, and thermal and pressure coefficients of properties.

10 [0067] A "sample" represents at least a portion of an entity to be tested for the presence and/or concentration of one or more components. Samples may be derived from, for example, animals, plants, bacteria, viruses, micro-organisms, blood, blood components, other bodily fluids, tissues, cells, genome, proteome, drinking water, soil, domestic waste, industrial waste, any food stuff - liquid or solid, crops, biological preparations, biochemical preparations.

15 [0068] The biotin used to label a sample may be any type capable of binding to streptavidin, including mutations and portions. Methods of biotinylation of a sample are described below.

20 [0069] By "solid support" herein is meant any solid support which is capable of immobilising components and/or samples. Such solid supports are known in the art and include, but are not limited to, nitrocellulose, glass slides, nylon, silane coated slides, nitrocellulose coated slides, plastics. A solid support may be capable of holding single spotted sample, multi-samples and/or micro-arrays etc. A solid support preferably comprises nitrocellulose.

25 [0070] Consecutive application and contact steps such as steps (a0), (a), (b), (c) and (d) are preferably carried out so that at least part of the contact area of each step is the same. Contacting may be effected at more than one separated points on a solid support. Contacting may also be achieved by covering a surface of a support with a single reagent. Contacting may also be achieved by a manual method or by using a device, resulting in an action including, but not limited to spotting, pipetting, printing, jet printing, dropping, soaking etc. According to an aspect of the invention, at least 30 part of, and preferably most of the area of application or contact in steps (a0), (a), (b), (c) and (d), where applicable, is the same.

35 [0071] By "reading" as used herein means determining from the change in the properties of the solid support at the position where the sample or probe is applied, the concentration of the components i.e. a quantitative reading. By "reading" as used herein also means determining from the change in the properties of the solid support at the position where the sample or probe is applied, whether a component is present i.e. a qualitative reading. According to the invention a change in the property of the solid support may be a colour change (e.g. from white to red, from white to black, from white to grey) and/or a change in electrical conductivity and/or a change in magnetic field at the position where the sample or probe is applied. It is within the scope of the invention that a change in property may be read by surface plasmon resonance or ellipsometry.

40 [0072] Reading may mean using normal vision to detect a colour change on the solid support to determine the presence or absence of a component or to determine the concentration of a component. It is within the scope of the invention that the reading may be taken using a colour chart that allows a comparison of the colour of the sample with that of known concentrations of probe or component. It is within the scope of the invention that a colour change disclosed herein may be read with or without the aid of electronic and optical measuring equipment. For example, a colour change of the solid support may be read by means of a reflectance reader as discussed below.

45 [0073] Using a reflectance reader to measure a colour change leads to accurate measurements and allows the determination of the concentration of the probe or component. The concentration of an unknown component can be calculated by interpolation on a standard curve obtained with several concentrations of probe or component.

50 [0074] Reading may mean using an optical scanner to ascertain a colour change on the solid support to determine the presence or absence of a component or to determine the concentration of a component.

55 [0075] Reading may also mean using a device to measure a change of electrical conductivity or electrical current at the position on the solid support where the sample or probe is applied, to determine the concentration of the components. The inventors have found that the use of electrically-conducting metal particles in steps (c) and/or (d) according to the invention results in a change of electrical conductivity of the solid support. The change can be conveniently and accurately read using a device capable of detecting a change in conductivity and/or current across a solid support. Said device may comprise one or more of the following features: one or more electrical contact probes, circuitry to measure conductivity and/or current, an analogue to digital converter. According to one example, one probe of the device contacts an upper surface of the solid support at the position where the sample or probe is applied, and a second probe contacts the same

position on the lower surface; the conductivity and/or current across said probes is measured by the device. According to another example, one probe of the device contacts an upper surface of the solid support at the position where the sample or probe is applied, and the whole of the lower surface of the solid support contacts a conducting plate; the conductivity and/or current across said probe and plate is measured by the device. The latter example has the convenience that the measurement of more than one sample requires movement of only the probe contacting the upper surface.

[0076] Reading may also mean using a device to measure a change of magnetic field at a position on the solid support where a sample or probe is applied, to determine the concentration of the components. The use of metal particles which are also magnetic in steps (c) and/or (d) according to the invention can result in a change of magnetic field of the solid support. The change can be conveniently and accurately read using a device capable of detecting a change in magnetic field on a solid support. Said device may comprise one or more of the following features: one or more magnetic-field detecting probes, circuitry to measure magnetic fields, an analogue to digital converter. According to one example, a magnetic-field detecting probe of the device scans the surface of the solid support at the position where the sample or molecular probe is applied, and the magnetic-field of the solid support is measured by the device.

[0077] Reading may also mean using a device which utilises surface plasmon resonance to detect a change in surface properties on the solid support where a sample or probe is applied.

[0078] Reading may also mean using a device which detects a change in polarised light reflected from surface of the solid support where a sample or probe is applied. An example of such a device is an ellipsometer.

In vivo imaging

[0079] Another aspect but not being part of the present invention is a method for enhancing imaging by magnetic resonance of one or more components in a system, each component capable of binding to a probe comprising the steps of:

- (i) adding a biotin-labelled probe to a system,
- (ii) adding streptavidin-metal particle complex to said system, and
- (iii) recording an image of the system using magnetic resonance imaging.

[0080] The inventors have found that the complexes formed using metal particles of a nanometer size or subnanometer size in step (ii), e.g. 0.8nm, have fundamentally different characteristics when compared with conjugates built around larger particles which make them suitable for use in enhancing in *in vivo* imaging. The small nanoparticles have a tight particle surface curvature which makes them less likely to attract a structured water dipole layer around it. Thus, the hydrodynamic radius is hence reduced. Also, these small metal particles carry less net negative charge, thus, they undergo less charge determined repulsion when approaching the sample surface. These characteristics appear to result in a better permeability in biological systems, organs and organisms. Furthermore, the nanoparticles of step (ii) are so small, they do not cause steric hinderance. This makes them ideal as markers for visualizing pathways, for example, of human metabolism.

[0081] A system according to the imaging method may be a biological entity in which the presence and distribution of components is of interest. Examples of systems include humans, animals, plants, cells, tissues, organs, micro-organisms.

[0082] The method for enhancing the imaging of components in a system can be performed by a technician.

[0083] The method for enhancing the imaging of components in a system can be used to detect the susceptibility to medical conditions. The method for enhancing the imaging of components in a system can be used to detect the medical conditions which exists in a patient. Examples of components and conditions are provided in Table 1.

[0084] A "component" as used herein means any substance capable of binding to a probe enabling identification of said component. Examples of components include, but are not limited to DNA, cDNA, mRNA, RNA, nucleic acids, proteins, polypeptides, glycoproteins, receptors, ligands, signalling proteins, metabolites, toxins, cells, bacteria, viruses etc. Examples of components are provided in Table 1. Examples of types of components useful for detecting by imaging include receptors, cellular surface proteins, ribonucleic acids, desoxyribonucleic acids, cytoplasmic antigens, nuclear antigens, membrane antigens, hormones, metabolites, tumour antigens, mitochondrial proteins, mitochondrial DNA and mitochondrial RNA, nuclear proteins.

[0085] A "probe" as used herein means any compound capable of specific binding to a component. A nucleic acid oligomer binding to a gene, a ligand binding to a receptor, an antibody binding to an antigen are examples of probe/component interactions according to the invention. According to the present invention, the affinity of binding between a probe and a component is better than 10 μ M, 5 μ M, 2 μ M, 1 μ M, 0.1 μ M, 0.01 μ M or 1 nM. Examples of probes include but are not limited to nucleic acids, PNAs, proteins, peptides, antibodies, ligands, receptors etc.

[0086] The biotin used to label a probe may be any type capable of binding to streptavidin, including chemical variations thereof. Methods of biotinyling a probe are described below.

[0087] By "streptavidin-metal particle complex" as used herein is a complex comprising streptavidin and/or avidin and one or more metal particles. The streptavidin is any type of streptavidin capable of binding to biotin, including portions

or mutations of streptavidin. The avidin is any type of avidin capable of binding to biotin, including portions or mutations of avidin. In one aspect of the invention, metal particles may be bound to streptavidin and/or avidin by non-covalent forces. In another aspect of the invention, metal particles may be bound to streptavidin and/or avidin by covalent bonding. Methods of providing streptavidin and/or avidin with one or more metal particles are known to the skilled person. The types of metal particle and their diameters are described in detail below.

5 [0088] A "conjugate" as used herein comprises one or more polymers labeled with one or more biotin molecules, and metal particles bound to said polymer. The biotin used to label a polymer may be any type capable of binding to streptavidin and/or avidin, including chemical variations thereof. According to one aspect of the invention, biotin is covalently attached to a polymer - methods therefor are described below. According to another aspect of the invention, the number of biotin molecules attached to a polymer may be less than 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000, and preferably in the range 1 to 500, 1 to 400, 1 to 300, 1 to 200, 1 to 100, and most preferably in the range 5 to 100.

10 [0089] A "polymer" as present in a conjugate according to the invention is any polymeric substance with a molecular weight greater than 500 Da, 1000 Da, 1500 Da, 2000 Da or 2500 Da, and most preferably greater than 500 Da. It is an aspect of the invention that a polymer exhibits no specific binding towards a sample or probe. It is an aspect of the invention that a polymer is biologically inert. In other words it has no specific binding towards other biological molecules, and other biological molecules do not specifically bind to it. It is an aspect of the invention that a polymer is capable of binding one or more metal particles by electrostatic or covalent interactions. The polymers which can be employed in the present invention may be chemically synthesized polymers or naturally occurring polymers. Examples of the chemically synthesized polymers include vinyl polymers, aramid polymers, polyvinylamine, poly(vinyl alcohol), poly(N-vinyl-carbazole), poly(vinylpyridine), polypyrrole, polyphenyl polymers, poly(phenylene sulfide), poly(vinylidene fluoride), poly(methyl methacrylate), polymethylene polymers, polyimidazole, polyimide, polystyrene, olefin polymers, elastomers, engineering polymers, polyolefin, polyester, polycarbonate, engineering plastics, epoxy polymers, phenolic polymers, polyurethane, polydinene polymers, acrylic polymers, polyacrylamide, polyamide, polyacetal, polyether, polyacetylene, 15 polyaniline, polyisobutylene, polyisoprene, poly(ethylene terephthalate), polyene polymers, poly(vinylidene chloride), poly(vinyl chloride), polycarbonate, poly(vinyl acetate), polypropylene, ethylene polymers, ion-exchange resins (e.g., Nafion), and silicone derivatives. Examples of the naturally occurring polymers include agarose, gellan gum, cellulose polymers (e.g., hydroxyethyl cellulose, hydroxypropyl cellulose, and carboxymethyl cellulose), dextrin, dextrin, alginate salts, hyaluronate salts, poly(glutamic acid), poly(lysine), chitosan, lignin, carageenan, silk fibroin, agar, polypeptide, 20 polypeptide, polysaccharide, polyethylene glycol, nucleic acid chain, peptic nucleic acid (PNA), polyglycoprotein, and gelatin. These polymers may also be derivatives thereof, copolymers obtained from one or more species selected from among the polymers and/or polymer derivatives, polymer-polymer complexes, polymer alloys, polymer blends, and polymer composites. A polymer may exhibit one or more of the above features. It is an aspect of the invention that a conjugate comprises essentially one polymer. It is another aspect of the invention that a conjugate comprises more than 25 one polymer. It is an aspect of the invention that a polymer is albumin or dextran polymer.

30 [0090] In one aspect of the invention, metal particles are bound to polymer by non-covalent forces. In another aspect of the invention, metal particles are bound to polymer by covalent bonding. Methods of providing polymer one or more metal particles are known to the skilled person. The types of metal particle and their diameters are described in detail below.

35 [0091] According to an aspect of the invention, when a conjugate comprises more than one polymer, all the polymer molecules are the same (e.g. at least two molecules of albumin). Alternatively, when a conjugate may comprise more than one polymer, at least two polymers are different (e.g. one molecule of albumin, and one molecule of dextran).

40 [0092] According to another aspect of the invention, when a conjugate comprises more than one biotin, all the biotin molecules are the same (e.g. at least two molecules of biotin). Alternatively, when a conjugate may comprise more than one biotin, at least two biotins are different (e.g. one molecule of biotin, and one molecule of modified biotin).

45 [0093] The process of biotinylation of a sample, probe or polymer is known to the skilled artisan and can be performed on proteins, peptides, nucleic acids or other compounds. For example, nucleic acid may be biotinylated by performing a polymerase chain reaction using biotinylated primer(s) specific for the sequence of interest. Peptides and proteins may be biotinylated using biotinylation reagents which, for example, biotinylate the C-terminus, the N-terminus and/or reactive side chains of the protein or peptide. Organic polymeric chains may be biotinylated using biotinylation reagents which, for example, target reactive side chains. Optionally, flexible linkers, such as alkyl chains, polynucleotide chains, polypeptide chains, etc. may be introduced between the biotin and the target. Such linkers may further enhance detection by reducing steric hinderance caused by the polypeptide. The present invention includes any method for the biotinylation of a sample, probe or polymer.

50

Metal particles

55 [0094] The metal particles of the streptavidin-metal particle complex, or conjugate may be any which provide a colour

change, a change in electrical conductance, a change in magnetic field, or improved contrast in *in vivo* imaging.

[0095] The particles suitable for use according to the invention include one or more of gold, silver, iron, nickel, gadolinium, lead, uranium, caesium, platinum, palladium, rhodium, technetium, tellurium, selenium, silicon (silicium), copper, tin, rhenium, europium, aluminium, germanium, chromium, cadmium, niobium, titanium, magnesium, manganese, molybdenum, antimony, americium, lithium, wolfram, thallium, ruthenium, osmium, iridium, and/or metallic substances conducting or semi-conducting.

[0096] The transition metals that can be employed in the present invention encompass particles composed of any transition metal element species. Examples of the transition metals which can be employed include one or more of Sc, Y, La, Ac (scandium-group elements); Ti, Zr, Hf (titanium-group elements); V, Nb, Ta (vanadium-group elements); Cr, Mo, W (chromium-group elements); Mn, Tc, Re (manganese-group elements); Fe, Ru, Os (iron-group elements); Co, Rh, Ir (cobalt-group elements); Ni, Pd, Pt (nickel-group elements); Cu, Ag and Au (copper-group elements). Among these transition metal elements, noble metals such as platinum, palladium, rhodium, iridium, ruthenium, osmium, silver, and gold are preferred.

[0097] Examples of transition metals include noble metal complexes and organometallic compounds of noble metal. Specific examples include platinum complexes, palladium complexes, rhodium complexes, iridium complexes, ruthenium complexes, osmium complexes, silver complexes, gold complexes, and non-stoichiometric compounds thereof; and ions of a variety of noble metal complexes; e.g., alkyl complexes, aryl complexes, metallacycle complexes, carbene complexes, olefin complexes, arene complexes, eta-aryl complexes, cyclopentadienyl complexes, hydrido complexes, carbonyl complexes, oxo complexes, and nitrogen complexes.

[0098] It is an aspect of the invention that metal particles of the streptavidin-metal particle complex and conjugate are the same metal particle (e.g. both the complex of step (c) and the conjugate of step (d) comprise gold particles). It is an aspect of the invention that the metal particles of the streptavidin-metal particle complex and the metal particles of the conjugate are different (e.g. the complex of step (c) may comprise gold particles, the conjugate of step (d) may comprise silver particles). It is an aspect of the invention that the metal particles of the complex or conjugate is an heterologous mix of metal particles (e.g. the complex of step (c) may comprise a mixture of gold and silver particles).

[0099] According to one aspect of the invention, metal particles preferred for use in detecting components in a sample whereby a colour change is read include, but are not limited to one or more of gold, silver, palladium, rhodium, iridium, platinum, and nickel.

[0100] According to another aspect of the invention, metal particles preferred for use in detecting components in a sample whereby a change in electrical conductance is read include, but are not limited to one or more of gold, silver, iron, copper, and nickel.

[0101] According to another aspect of the invention, metal particles preferred for use in detecting components in a sample whereby a change in magnetic field is read include, but are not limited to one or more of gold, silver, and iron.

[0102] According to another aspect of the invention, metal particles preferred for use in enhancing *in vivo* imaging according to the invention include, but are not limited to one or more of iron and gadolinium.

[0103] According to one aspect of the invention, metal particles may be of any average diameter in the nanometer or sub-nanometer range. In another aspect, the metal particles may have an average diameter of 0.6, 0.8 nm, 1 nm, 2 nm, 3 nm, 4 nm, 5 nm, 6 nm, 7 nm, 8 nm, 9 nm, 10 nm, 11 nm, 12 nm, 13 nm, 14 nm, 15 nm, 16 nm, 17 nm, 18 nm, 19 nm, 20 nm, 21 nm, 22 nm, 23 nm, 24 nm, 25 nm, 26 nm, 27 nm, 28 nm, 29 nm, 30 nm, 31 nm, 32 nm, 33 nm, 34 nm, 35 nm, 36 nm, 37 nm, 38 nm, 39 nm, 40 nm and 0.6 to 1.0 nm, 1.0 to 5.0 nm, 5.0 to 10 nm, 10 to 15 nm, 15 to 20 nm, 20 to 25 nm, 25 to 30 nm, 30 to 35 nm, 35 to 40 nm, and preferably 0.6 to 40 nm.

[0104] According to a preferred aspect of the invention, the streptavidin-metal particle complex or conjugate comprises one or more particles of gold with a diameter of 0.6 to 40 nm.

[0105] According to a preferred aspect of the invention, the streptavidin-metal particle complex, or conjugate comprises one or more particles of silver with a diameter of 0.6 to 40 nm.

[0106] According to a preferred aspect of the invention, the streptavidin-metal particle complex or conjugate comprises one or more particles of platinum with a diameter of 0.6 to 40 nm.

[0107] According to a preferred aspect of the invention, the streptavidin-metal particle complex or conjugate comprises one or more particles of palladium with a diameter of 0.6 to 40 nm.

[0108] The number of metal particles present in a complex or a conjugate may be less than 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000, and preferably in the range 5 to 50000, 5 to 100,000, to 500,000, 5 to 1,000,000.

[0109] The "metal enhancement reagent" of step (f) is any metal-containing reagent wherein the metal precipitates due to reduction. Examples include but are not limited to a silver enhancement reagent by Aurion (the Netherlands), BBI (UK), Sigma-Aldrich (USA), or Amersham (UK).

Superparamagnetic particle

[0110] One aspect of the invention, the streptavidin metal-particle complex and/or the conjugate comprise superparamagnetic particles.

5 [0111] According to an aspect of the invention the streptavidin-metal particle complex in step (c) and/or the conjugate in step (d) comprise one or more superparamagnetic particles, and the solid support is read for any change in colour.

[0112] According to another aspect of the invention, the streptavidin-metal particle complex or conjugate comprise one or more superparamagnetic particles, and the solid support is read for any change in electrical conductivity or magnetic field.

10 [0113] According to another aspect of the invention, the streptavidin-metal particle complex in step (c) comprises one or more superparamagnetic particles, steps (d) and (e) are not performed, and the solid support is read for any change in electrical conductivity or magnetic field.

[0114] Since binding of a streptavidin-metal particle complex and optionally conjugate comprising superparamagnetic particles also leads a change in electrical conductivity, this characteristic can be conveniently measured using a reading 15 device as mentioned above, without the need for precision optics. The use of such particles also leads to a change in the magnetic flux, which can be conveniently read by a reading device as mentioned above.

[0115] According to another aspect of the invention, streptavidin-metal particle complex in step (ii) comprises one or more superparamagnetic particles. A supermagnetic particle provides high sensitivity and contrast when used in magnetic resonance imaging.

20 [0116] Examples of superparamagnetic particles are known in the art and include, but are not limited to is iron, latex coated iron, iron oxide, and latex coated iron oxide.

[0117] According to another aspect of the invention, a superparamagnetic particle has a magnetic susceptibility of in the range 1 to 100 emu/g, 10 to 80 emu/g, 10 to 70 emu/g, 10 to 50 emu/g, 20 to 50 emu/g and preferably approximately 40 emu/g.

25 [0118] According to another aspect of the invention, a superparamagnetic particle has an iron oxide content of in the range 10 to 80%, 20 to 80 %, 30 to 80%, 40 to 80%, 50 to 80%, 60 to 80%, 70 to 80%, 10 to 70%, 20 to 70%, 30 to 70%, 40 to 70%, 50 to 70%, 60 to 70%, and preferably approximately 70%.

[0119] According to one aspect of the invention, the diameter of a superparamagnetic particle is between 50 and 400nm, 50 and 300nm, 50 and 200nm, 50 and 100nm, 100 and 400nm, 100 and 300nm, 100 and 200nm, 200 and 30 400nm, 200 and 300nm, 150 and 250 nm, and is preferably 200nm.

[0120] According to one aspect of the invention, the number of superparamagnetic particles in the streptavidin-metal particle complex, or in the conjugate may be less than 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000, and preferably in the range 5 to 50000, 5 to 100,000, to 500,000, 5 to 1,000,000.

35 [0121] In another aspect of the invention, superparamagnetic particles are bound to streptavidin (or avidin) or polymer using electrostatic interactions. In another aspect of the invention, superparamagnetic particles are covalently bound to streptavidin (or avidin) or polymer.

Pretreatment

40 [0122] In one aspect of the invention, sample or probe is applied to the solid support without the addition of any extra reagents to the sample or probe prior to application. In another aspect of the invention, sample or probe is applied to the solid support after a preconditioning procedure which increases the concentration of salt in said samples. The salt may be any dissociating salt in the art, including, but not limited to sodium chloride, potassium chloride. The preconditioning may comprise the addition of a volume of salt solution of a known concentration to a volume of sample or probe. The preconditioning step may comprise the addition of a volume of salt solution of a known concentration to an unknown volume of sample or probe. The concentration of salt in the sample may be adjusted to lie in the range of 100 mM to 500 mM, 500 mM to 1 M, 1 M to 1.5 M, 1.5 M to 2 M, 2 M to 2.5 M, 2.5 M to 3 M, 3 M to 3.5 M, 3.5 M to 4 M, 3.5 M to 5 M, 0.5 M to 2.5 M, 0.5 M to 3 M, or 0.5 M to 4 M.

50 [0123] In another aspect of the invention, after the applying step in (a) the samples or probes are not dried or baked before step (b) is performed. In another aspect of the invention, the samples or probes applied to the solid support in step (a) are allowed to dry. Similarly, step (a0) may be followed by step (a) in the absence or presence of an intervening drying step. Methods of drying are known in the art and can include, but are not limited to, drying in the air, drying in a incubator, drying in a chamber under low pressure with optionally heating. According to another aspect of the invention, the samples or probes applied to the solid support are baked by exposed to a temperature of between 60 to 70 degrees

Celsius, 65 to 75 degrees Celsius, 70 to 80 degrees Celsius, 75 to 85 degrees Celsius, 80 to 90 degrees Celsius, 65 degrees Celsius, 70 degrees Celsius, 75 degrees Celsius, 80 degrees Celsius, 85 degrees Celsius or 90 degrees Celsius. The exposure time may be for no more than 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, 50 minutes, 55 minutes or 60 minutes. The samples or probes may be dried and then baked, 5 only dried, only baked.

Storage

[0124] In another aspect of the invention, after the applying step in (a) or (a0), the solid support is stored. The 10 temperature at which the solid support on which sample or probe has been applied is stored may be between 0 and 10 degrees Celsius, 2 and 10 degrees, 3 and 10 degrees Celsius, 4 and 10 degrees Celsius, 5 and 10 degrees Celsius, 6 and 10 degrees Celsius, 7 and 10 degrees Celsius, 0 and 5 degrees Celsius, 1 and 5 degrees Celsius, 2 and 5 degrees Celsius, 3 and 5 degrees Celsius, 1 degree Celsius, 2 degrees Celsius, 3 degrees Celsius, 4 degrees Celsius, 5 degrees Celsius, 6 degrees Celsius, 7 degrees Celsius, 8 degrees Celsius, 9 degrees Celsius, 10 degrees Celsius.

Wash steps

[0125] The introduction of wash steps in the method above, may be determined by the skilled artisan in accordance 20 with commonly understood protocols in immunoassays such as ELISA and Western blots. For example, one or more wash steps may be introduced after one or more contacting steps, using with a washing reagent such as a buffer. For example, washes may be performed after steps (a0), (a), (b), (c), (d), and (e), where applicable. Preferably, a wash is performed after every step. Examples of buffers include physiological solution, phosphate buffer saline (PBS), TRIS-buffer, SSC-buffer, SSPE-buffer, and buffers in which a nonspecific binding protein is added to reduce aspecific binding of reactive components.

Pre-applied probe solid supports

[0126] As described in some embodiments above, one or more probes may be applied to a solid support prior to the 30 application of sample. According to one embodiment of the present invention, a solid support is provided with probe pre-applied. In one aspect of the invention, the solid support with probe pre-applied is provided with probe located at one or more positions, said probe recognising the same component. In one aspect of the invention, the solid support with probe pre-applied is provided with probe located one or more positions, said probe recognising different components. A method in which the solid support is provided with probe pre-applied enables a sample to be assayed for components without the necessity for performing probe application steps. Furthermore, a method using a solid support with probe 35 pre-applied, and probe recognising more than one component, enables single samples to be analysed for several components with a single incubation. For example, a single solid support may be used to detect several cancerous or pre-cancerous conditions by screening a single sample.

[0127] It is one advantage of the invention that it does not necessarily require an optical reading device such as a 40 laser scanner or back-scatter measuring equipment, and hence is convenient for use in environments away from laboratory conditions. The invention allows quantitative and/or qualitative results to be obtained at the location at which the sample was taken, for example, in a general practitioner's surgery, in an individual's home, in hospitals, generally 'in the field' without any specialist analytical instruments. Furthermore, the invention provides an assay that is as sensitive as, or more sensitive than assays which use fluorescence. Furthermore, since specialised measuring equipment is not necessarily required, the assay could be performed by a non-specialist.

Kit

[0128] Another aspect of the present invention is a kit for the quantitative and/or qualitative detection of components 50 in a sample comprising streptavidin-metal particle complex, solid support, and conjugate comprising biotin, polymer and metal particles bound to said polymer.

[0129] Such a kit allows a quantitative and/or qualitative detection of components on a solid support, and/or a detection 55 of components in a system by magnetic resonance.

[0130] A kit according to the present invention allows a skilled artisan to perform one or more steps of a method disclosed herein, in a convenient manner. The kit may allow a method of the present invention to be performed without the need to measure or determine the concentrations of reagents, so enabling a fast and reproducible assaying of one or more samples.

[0131] Another aspect of the present invention is a kit as described above, comprising a solid support, wherein said support is pre-loaded with one or more probes. In one aspect of the invention, the solid support is provided with probe

located one or more positions, said probe recognising the same component. In one aspect of the invention, the solid support is provided with probe located one or more positions, said probe recognising different components.. In another aspect of the invention, the solid support is provided with one or more probes which are capable of binding to the components listed in Table 1. Thus, a kit supplied with solid support in which the molecular probe is pre-applied enables a sample to be assayed for components without the necessity for performing application steps. Furthermore, a kit supplied with solid support pre-spotted with more than one molecule probe, each capable of recognising a different component enables a single sample to be analysed for several components with a single incubation. For example, a single solid support may be used to detect for several pre-cancerous or cancerous conditions as described below by screening a single sample.

5 [0132] Another aspect of the present invention is a kit for the detection of components in a sample as disclosed herein, further comprising one or more biotin-labelled probes. Each probe may be specific for a component in a sample to be detected.

10 [0133] Another aspect of the present invention is a kit for the detection of components in a sample as disclosed herein further comprising metal enhancement reagent. According to one aspect of the invention, metal enhancement reagent is present in one or more containers. Examples of containers according to the invention are indicated above.

15 [0134] Another aspect of the present invention is a kit for the detection of components in a sample as disclosed herein as disclosed herein, further comprising reagent for the biotinylation of probes or sample to be tested. As already mentioned above, method and reagent for biotinylation of probes and sample are known in the art.

20 [0135] According to one aspect of the invention, complex, conjugate and/or reagents for biotinylation are present in separate containers. According to the invention a container may be any sealed or resealable vessel suitable for carrying a quantity of complex, conjugate and/or reagents for biotinylation. Examples include, but are not limited to screw cap vials, push cap vials, break-seal-to-open vials, syringes.

25 [0136] In another aspect of the invention, the kit comprises one or more additional parts to enable the skilled person to perform one or more of the method steps disclosed herein. The kit may comprise one or more additional reagents enabling the skilled person to perform the complete method. Alternatively, the kit may comprise a minimum number of parts, such as only streptavidin metal-particle complex, for example, that enables a skilled person to perform the method disclosed herein. A kit according to the invention may comprise any combination of parts or reagents disclosed herein to enable a skilled person to perform a method disclosed herein.

30 [0137] In another aspect of the invention, the kit contains instructions for use. In another aspect of the invention the instructions describing a method of the invention as disclosed herein.

35 [0138] In another aspect of the invention, the kit may be used for the diagnosis of disease, susceptibility of disease, monitoring the progress of disease, monitoring the progress of disease during treatment, testing of food, water, soil, testing for contamination, testing for the presence of genetically modified (GM) food components and/or organisms.

35 *Detection of conditions*

40 [0139] Another aspect of the present invention is a method and/or kit as disclosed herein for detecting the presence of a component in a sample, wherein the sample to be tested may comprise one or more components related to a disease. Another aspect of the present invention is a method and/or kit as disclosed herein for imaging components in a system by magnetic resonance, wherein the system may comprise one or more components related to a disease. According to one embodiment, a probe is an antibody directed against the DNA, mRNA, cDNA or polypeptide representing said component or part thereof in the diseased individual. Alternatively, a probe is a nucleic acid (e.g. DNA, PNA, RNA) oligomer which is capable of hybridizing to the DNA, mRNA, and/or cDNA representing said component or part thereof in the diseased individual. A method and/or kit of the invention uses one or more of the embodiments disclosed herein.

45 Examples of components which are associated with diseases and which are detectable using the method and/or kit of the invention by way of one or more probes directed there to are provided in Table 1.

50 [0140] A method and/or kit according to the present invention may be used for the diagnosis and detection of cancer in individuals, for example, for the diagnosis of a type of cancer, for the early detection of cancer, to monitor the progress of cancer in individuals already diagnosed with the disease, to detect a relapse of cancer. Cancer is still a major disease and to prolong life expectancy, it would be advantageous to detect the disease in a pre-clinical stage. A diagnostic assay as disclosed herein makes this possible. Non-limiting examples of components to which cancer or several hereditary conditions are associated with are provided in Table 1 and, one or more of which are detectable using the method and/or kit of the invention. A diagnosis may require detection of one or more of the listed molecules.

TABLE 1: List of components which are disease-related and are detectable using the kit and/or method of the present invention.

Number	Component	Comments
1.	BRCA1	breast cancer 1, early onset
2.	TP53	tumor protein p53 (Li-Fraumeni syndrome)
3.	CFTR	cystic fibrosis transmembrane conductance regulator, ATP-binding cassette (sub-family C, member 7)
4.	APP	amyloid beta (A4) precursor protein (protease nexin-II, Alzheimer disease)
5.	APOE	apolipoprotein E
6.	BRCA2	breast cancer 2, early onset
7.	HBB	hemoglobin, beta
8.	APC	adenomatosis polyposis coli
9.	MYC	v-myc myelocytomatosis viral oncogene homolog (avian)
10.	HD	huntington (Huntington disease)
11.	BCL2	B-cell CLUlymphoma 2
12.	ABL1	v-abl Abelson murine leukemia viral oncogene homolog 1
13.	BAX	BCL2-associated X protein
14.	DMD	dystrophin (muscular dystrophy, Duchenne and Beckertypes), includes DDX142, DDX164, DDX206, DDX230, DDX239, DDX268, DDX269, DDX270, DDX272
15.	CDKN2A	cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)
16.	ATM	ataxia telangiectasia mutated (includes complementation groups A, C and D)
17.	TNF	tumor necrosis factor (TNF superfamily, member 2)
18.	RB1	retinoblastoma 1 (including osteosarcoma)
19.	VEGF	vascular endothelial growth factor
20.	ERBB2	v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
21.	FGG	fibrinogen, gamma polypeptide
22.	HPRT1	hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan syndrome)
23.	MAPT	microtubule-associated protein tau
24.	MDM2	Mdm2, transformed 3T3 cell double minute 2, p53 binding protein (mouse)
25.	RUNX1	runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene)

(continued)

Number	Component	Comments
26.	SOD1	superoxide dismutase 1, soluble (amyotrophic lateral sclerosis 1 (adult))
27.	CDKN1A	cyclin-dependent kinase inhibitor 1A (p21, Cip1)
28.	PAX6	paired box gene 6 (aniridia, keratitis)
29.	NF1	neurofibromin 1 (neurofibromatosis, von Recklinghausen disease, Watson disease)
30.	FN1	fibronectin 1
31.	CASP3	caspase 3, apoptosis-related cysteine protease
32.	PAH	phenylalanine hydroxylase
33.	GAPD	glyceraldehyde-3-phosphate dehydrogenase
34.	PTEN	phosphatase and tensin homolog (mutated in multiple advanced cancers 1)
35.	HFE	hemochromatosis
36.	FGFR3	fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism)
37.	EGFR	epidermal growth factor receptor (erythroblastic leukemia viral (v-erb-b) oncogene homolog, avian)
38.	DSCR1	Down syndrome critical region gene 1
39.	MLH1	mutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli)
40.	PABPC1	poly(A) binding protein, cytoplasmic 1
41.	CYP3A5	cytochrome P450, subfamily IIIA (nifedipine oxidase), polypeptide 5
42.	PSEN1	presenilin 1 (Alzheimer disease 3)
43.	FBN1	fibrillin 1 (Marfan syndrome)
44.	MSH2	mutS homolog 2, colon cancer, nonpolyposis type 1 (E. coli)
45.	AKT1	v-akt murine thymoma viral oncogene homolog 1
46.	CCND1	cyclin D1 (PRAD1: parathyroid adenomatosis 1)
47.	MTHFR	5,10-methylenetetrahydrofolate reductase (NADPH)
48.	AR	androgen receptor (dihydrotestosterone receptor; testicular feminization; spinal and bulbar muscular atrophy; Kennedy disease)
49.	TGFB1	transforming growth factor, beta 1 (Camurati-Engelmann disease)
50.	IL6	interleukin 6 (interferon, beta 2)
51.	KRAS2	v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog

(continued)

Number	Component	Comments
52.	HRAS	v-Ha-ras Harvey rat sarcoma viral oncogene homolog
53.	RET	ret proto-oncogene (multiple endocrine neoplasia and medullary thyroid carcinoma 1, Hirschsprung disease)
54.	PPARG	peroxisome proliferative activated receptor, gamma
55.	ACTB	actin, beta
56.	CDH1	cadherin 1, type 1, E-cadherin (epithelial)
57.	ESR1	estrogen receptor 1
58.	IGF1	insulin-like growth factor 1 (somatomedin C)
59.	GSTP1	glutathione S-transferase pi
60.	IL8	interleukin 8
61.	LPL	lipoprotein lipase
62.	FMR1	fragile X mental retardation 1
63.	WT1	Wilms tumor 1
64.	IL1B	interleukin 1, beta
65.	CYP1A1	cytochrome P450, subfamily I (aromatic compound-inducible), polypeptide 1
66.	CTNNB1	catenin (cadherin-associated protein), beta 1 (88kD)
67.	ITGA5	integrin, alpha 5 (fibronectin receptor, alpha polypeptide)
68.	FOS	v-fos FBJ murine osteosarcoma viral oncogene homolog
69.	KIT	v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
70.	ATP7B	ATPase, Cu++ transporting, beta polypeptide (Wilson disease)
71.	IGF2	insulin-like growth factor 2 (somatomedin A)
72.	JUN	v-jun sarcoma virus 17 oncogene homolog (avian)
73.	CYP2C19	cytochrome P450, subfamily IIC (mephénytoïn 4-hydroxylase), polypeptide 19
74.	BCR	breakpoint cluster region
75.	FGFR2	fibroblast growth factor receptor 2 (bacteria-expressed kinase, keratinocyte growth factor receptor, craniofacial dysostosis 1, Crouzon syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome)
76.	CASP8	caspase 8, apoptosis-related cysteine protease
77.	INSR	insulin receptor
78.	G6PD	glucose-6-phosphate dehydrogenase

(continued)

Number	Component	Comments
79.	IL4	interleukin 4
80.	DRD2	dopamine receptor D2
81.	FGFR1	fibroblast growth factor receptor 1 (fms-related tyrosine kinase 2, Pfeiffer syndrome)
82.	COL1A1	collagen, type I, alpha 1
83.	BLM	Bloom syndrome
84.	NF2	neurofibromin 2 (bilateral acoustic neuroma)
85.	MMP1	matrix metalloproteinase 1 (interstitial collagenase)
86.	IL2	interleukin 2
87.	GRB2	growth factor receptor-bound protein 2
88.	BCL2L1	BCL2-like 1
89.	PSEN2	presenilin 2 (Alzheimer disease 4)
90.	TNFRSF6	tumor necrosis factor receptor superfamily, member 6
91.	CD44	CD44 antigen (homing function and Indian blood group system)
92.	MMP9	matrix metalloproteinase 9 (gelatinase B, 92kD gelatinase, 92kD type IV collagenase)
93.	ABCB1	ATP-binding cassette, sub-family B (MDR/TAP), member 1
94.	GSTM1	glutathione S-transferase M1
95.	IL1A	interleukin 1, alpha
96.	MET	met proto-oncogene (hepatocyte growth factor receptor)
97.	ABO	ABO blood group (transferase A, alpha 1-3-N-acetylgalactosaminyltransferase; transferase B, alpha 1-3-galactosyltransferase)
98.	NRAS	neuroblastoma RAS viral (v-ras) oncogene homolog
99.	NAT2	N-acetyltransferase 2 (arylamine N-acetyltransferase)
100.	EGR1	early growth response 1
101.	TTR	transthyretin (prealbumin, amyloidosis type I)
102.	SOD2	superoxide dismutase 2, mitochondrial
103.	SCYA2	small inducible cytokine A2 (monocyte chemotactic protein 1)
104.	NOS3	nitric oxide synthase 3 (endothelial cell)
105.	CDC2	cell division cycle 2, G1 to S and G2 to M
106.	STAT1	signal transducer and activator of transcription 1, 91 kD

(continued)

Number	Component	Comments
107.	SNCA	synuclein, alpha (non A4 component of amyloid precursor)
108.	CLU	clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed prostate message 2, apolipoprotein J)
109.	CDKN1B	cyclin-dependent kinase inhibitor 1B (p27, Kip1)
110.	TYR	tyrosinase (oculocutaneous albinism IA)
111.	MADH4	MAD, mothers against decapentaplegic homolog 4 (Drosophila)
112.	CDK2	cyclin-dependent kinase 2
113.	MMP3	matrix metalloproteinase 3 (stromelysin 1, progelatinase)
114.	YWHAZ	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide
115.	CASP1	caspase 1, apoptosis-related cysteine protease (interleukin 1, beta, convertase)
116.	PCNA	proliferating cell nuclear antigen
117.	HLA-A, -B, -C	major histocompatibility complex, class I, A, B, C
118.	APOB	apolipoprotein B (including Ag(x) antigen)
119.	CASP9	caspase 9, apoptosis-related cysteine protease
120.	NOS2A	nitric oxide synthase 2A (inducible, hepatocytes)
121.	IFNG	interferon, gamma
122.	APOA1	apolipoprotein A-1
123.	AGT	angiotensinogen (serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 8)
124.	ADA	adenosine deaminase
125.	ICAM1	intercellular adhesion molecule 1 (CD54), human rhinovirus receptor
126.	CYP19	cytochrome P450, subfamily XIX (aromatization of androgens)
127.	SLC6A4	solute carrier family 6 (neurotransmitter transporter, serotonin), member 4
128.	TNFRSF1A	tumor necrosis factor receptor superfamily, member 1A
129.	CD4	CD4 antigen (p55)
130.	VWF	von Willebrand factor
131.	ACTA1	actin, alpha 1, skeletal muscle

(continued)

Number	Component	Comments
132.	MECP2	methyl CpG binding protein 2 (Rett syndrome)
133.	COMT	catechol-O-methyltransferase
134.	TERT	telomerase reverse transcriptase
135.	PKD	polycystic kidney disease 1 (autosomal dominant)
136.	F7	coagulation factor VII (serum prothrombin conversion accelerator)
137.	PMP22	peripheral myelin protein 22
138.	F5	coagulation factor V (proaccelerin, labile factor)
139.	PPARA	peroxisome proliferative activated receptor, alpha
140.	GCK	glucokinase (hexokinase 4, maturity onset diabetes of the young 2)
141.	MUC1	mucin 1, transmembrane
142.	SPP1	secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1)
143.	RAF1	v-raf-1 murine leukemia viral oncogene homolog 1
144.	IGF1R	insulin-like growth factor 1 receptor
145.	IL4R	interleukin 4 receptor
146.	DCC	deleted in colorectal carcinoma
147.	PML	promyelocytic leukemia
148.	PDGFRB	platelet-derived growth factor receptor, beta polypeptide
149.	AGTR1	angiotensin receptor 1
150.	UBE3A	ubiquitin protein ligase E3A (human papilloma virus E6-associated protein, Angelman syndrome)
151.	CREBBP	CREB binding protein (Rubinstein-Taybi syndrome)
152.	CYP1B1	cytochrome P450, subfamily 1 (dioxin-inducible), polypeptide 1 (glaucoma 3, primary infantile)
153.	AKT2	v-akt murine thymoma viral oncogene homolog 2
154.	PLAT	plasminogen activator, tissue
155.	CHRNA7	cholinergic receptor, nicotinic, alpha polypeptide 7
156.	TIMP1	tissue inhibitor of metalloproteinase 1 (erythroid potentiating activity, collagenase inhibitor)
157.	NFKB1	nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105)

(continued)

Number	Component	Comments
158.	STAT3	signal transducer and activator of transcription 3 (acute-phase response factor)
159.	CDC42	cell division cycle 42 (GTP binding protein, 25kD)
160.	VDR	vitamin D (1,25- dihydroxyvitamin D3) receptor
161.	NTRK1	neurotrophic tyrosine kinase, receptor, type 1
162.	VIM	vimentin
163.	TGFBR2	transforming growth factor, beta receptor II (70-80kD)
164.	DHFR	dihydrofolate reductase
165.	PTCH	patched homolog (Drosophila)
166.	CYP2A6	cytochrome P450, subfamily IIA (phenobarbital-inducible), polypeptide 6
167.	HSPCA	heat shock 90kD protein 1, alpha
168.	E2F1	E2F transcription factor 1
169.	CACNA1A	calcium channel, voltage-dependent, P/Q type, alpha 1A subunit
170.	LCK	lymphocyte-specific protein tyrosine kinase
171.	LGALS3	lectin, galactoside-binding, soluble, 3 (galectin 3)
172.	RARA	retinoic acid receptor, alpha
173.	PDZK1	PDZ domain containing 1
174.	ALDH2	aldehyde dehydrogenase 2 family (mitochondrial)
175.	PAX3	paired box gene 3 (Waardenburg syndrome 1)
176.	FGF2	fibroblast growth factor 2 (basic)
177.	GJB1	gap junction protein, beta 1, 32kD (connexin 32, Charcot-Marie-Tooth neuropathy, X-linked)
178.	LMNA	lamin A/C
179.	CAPN3	calpain 3, (p94)
180.	ADPRT	ADP-ribosyltransferase (NAD ⁺ ; poly (ADP-ribose) polymerase)
181.	TUBB	tubulin, beta polypeptide
182.	ABCA1	ATP-binding cassette, sub-family A (ABC1), member 1
183.	IL1RN	interleukin 1 receptor antagonist
184.	CTGF	connective tissue growth factor
185.	GSTT1	glutathione S-transferase theta 1
186.	DRD4	dopamine receptor D4
187.	HTR2A	5-hydroxytryptamine (serotonin) receptor 2A
188.	FHIT	fragile histidine triad gene

(continued)

Number	Component	Comments
189.	ETV6	ets variant gene 6 (TEL oncogene)
190.	PDGFB	platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog)
191.	PPP3R1	protein phosphatase 3 (formerly 2B), regulatory subunit B (19kD), alpha isoform (calcineurin B, type I)
192.	TIMP3	tissue inhibitor of metalloproteinase 3 (Sorsby fundus dystrophy, pseudoinflammatory)
193.	COL1A2	collagen, type I, alpha 2
194.	ITGB3	integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)
195.	COL3A1	collagen, type III, alpha 1 (Ehlers-Danlos syndrome type IV, autosomal dominant)
196.	ESR2	estrogen receptor 2 (ER beta)
197.	B2M	beta-2-microglobulin
198.	SDF1	stromal cell-derived factor 1
199.	F9	coagulation factor IX (plasma thromboplastin component, Christmas disease, hemophilia B)
200.	MAPK14	mitogen-activated protein kinase 14
201.	BAK1	BCL2-antagonist/killer 1
202.	ITGB1	integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)
203.	ACTG1	actin, gamma 1
204.	KDR	kinase insert domain receptor (a type III receptor tyrosine kinase)
205.	SCTR	secretin receptor
206.	LEPR	leptin receptor
207.	SP1	Sp1 transcription factor
208.	CDKN1C	cyclin-dependent kinase inhibitor 1C (p57, Kip2)
209.	MYCN	v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian)
210.	IL12B	interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40)
211.	IGF2R	insulin-like growth factor 2 receptor
212.	FLT1	fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor)
213.	CD36	CD36 antigen (collagen type I receptor, thrombospondin receptor)

(continued)

Number	Component	Comments
214.	FRD	Friedreich ataxia
215.	COL2A1	collagen, type II, alpha 1 (primary osteoarthritis, spondyloepiphyseal dysplasia, congenital)
216.	GSN	gelsolin (amyloidosis, Finnish type)
217.	CYP2E	cytochrome P450, subfamily IIE (ethanol-inducible)
218.	APAF1	apoptotic protease activating factor
219.	ANK1	ankyrin 1, erythrocytic
220.	SLC6A3	solute carrier family 6 (neurotransmitter transporter, dopamine), member 3
221.	CASP7	caspase 7, apoptosis-related cysteine protease
222.	MYH7	myosin, heavy polypeptide 7, cardiac muscle, beta
223.	JUNB	jun B proto-oncogene
224.	GHR	growth hormone receptor
225.	IRS1	insulin receptor substrate 1
226.	CASP10	caspase 10, apoptosis-related cysteine protease
227.	BDNF	brain-derived neurotrophic factor
228.	ATP7A	ATPase, Cu++ transporting, alpha polypeptide (Menkes syndrome)
229.	TCF1	transcription factor 1, hepatic; LF-B1, hepatic nuclear factor (HNF1), albumin proximal factor
230.	HGF	hepatocyte growth factor (hepatopoietin A; scatter factor)
231.	CYP17	cytochrome P450, subfamily XVII (steroid 17-alpha-hydroxylase), adrenal hyperplasia
232.	PTPN1	protein tyrosine phosphatase, non-receptor type 1
233.	ADRB3	adrenergic, beta-3-, receptor
234.	TNFSF6	tumor necrosis factor (ligand) superfamily, member 6
235.	ERCC5	excision repair cross-complementing rodent repair deficiency, complementation group 5 (xeroderma pigmentosum, complementation group G (Cockayne syndrome))
236.	VCAM1	vascular cell adhesion molecule 1
237.	TF	transferrin
238.	ACE	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1
239.	LRP1	low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)
240.	CDK5	cyclin-dependent kinase 5

(continued)

Number	Component	Comments
241.	ACACA	acetyl-Coenzyme A carboxylase alpha
242.	TNFRSF1B	tumor necrosis factor receptor superfamily, member 1B
243.	NOTCH3	Notch homolog 3 (Drosophila)
244.	ERBB3	v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
245.	CSK	c-src tyrosine kinase
246.	SCN5A	sodium channel, voltage-gated, type V, alpha polypeptide (long (electrocardiographic) QT syndrome 3)
247.	BCL6	B-cell CLL/lymphoma 6 (zinc finger protein 51)
248.	FYN	FYN oncogene related to SRC, FGR, YES
249.	CTSK	cathepsin K (pycnodysostosis)
250.	SPARC	secreted protein, acidic, cysteine-rich (osteonectin)
251.	NFKB2	nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)
252.	SCYA5	small inducible cytokine A5 (RANTES)
253.	BMP4	bone morphogenetic protein 4
254.	ATP2A2	ATPase, Ca ⁺⁺ transporting, cardiac muscle, slow twitch 2
255.	NR3C1	nuclear receptor subfamily 3, group C, member 1
256.	THBS1	thrombospondin 1
257.	CETP	cholesterol ester transfer protein, plasma
258.	PTPRC	protein tyrosine phosphatase, receptor type, C
259.	NME1	non-metastatic cells 1, protein (NM23A) expressed in
260.	TGFBI	transforming growth factor, beta-induced, 68kD
261.	SREBF1	sterol regulatory element binding transcription factor 1
262.	MMP14	matrix metalloproteinase 14 (membrane-inserted)
263.	KCNQ1	potassium voltage-gated channel, KQT-like subfamily, member 1
264.	TUBA1	tubulin, alpha 1 (testis specific)
265.	SELE	selectin E (endothelial adhesion molecule 1)
266.	ATRX	alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. cerevisiae)
267.	IL2RG	interleukin 2 receptor, gamma (severe combined immunodeficiency)

(continued)

Number	Component	Comments
268.	IGFBP3	insulin-like growth factor binding protein 3
269.	JAK3	Janus kinase 3 (a protein tyrosine kinase, leukocyte)
270.	CSF1R	colony stimulating factor 1 receptor, formerly McDonough feline sarcoma viral (v-fms) oncogene homolog
271.	SHC1	SHC (Src homology 2 domain containing) transforming protein 1
272.	CASP4	caspase 4, apoptosis-related cysteine protease
273.	PLA2G2A	phospholipase A2, group IIA (platelets, synovial fluid)
274.	CXCR4	chemokine (C-X-C motif), receptor 4 (fusin)
275.	CDKN2B	cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4)
276.	ARHA	ras homolog gene family, member A
277.	SHH	sonic hedgehog homolog (Drosophila)
278.	RARB	retinoic acid receptor, beta
279.	MME	membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10)
280.	CA2	carbonic anhydrase II
281.	PRKDC	protein kinase, DNA-activated, catalytic polypeptide
282.	HIF1A	hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)
283.	PRKCA	protein kinase C, alpha
284.	CASP2	caspase 2, apoptosis-related cysteine protease (neural precursor cell expressed, developmentally down-regulated 2)
285.	DMBT1	deleted in malignant brain tumors 1
286.	TGFB2	transforming growth factor, beta 2
287.	TSC2	tuberous sclerosis 2
288.	PSAP	prosaposin (variant Gaucher disease and variant metachromatic leukodystrophy)
289.	XPC	xeroderma pigmentosum, complementation group C
290.	THRA	thyroid hormone receptor, alpha (erythroblastic leukemia viral (v-erb-a) oncogene homolog, avian)
291.	ERCC2	excision repair cross-complementing rodent repair deficiency, complementation group 2 (xeroderma pigmentosum D)
292.	MAPK1	mitogen-activated protein kinase 1

(continued)

Number	Component	Comments
293.	ATP6B1	ATPase, H ⁺ transporting, lysosomal (vacuolar proton pump), beta polypeptide, 56/58kD, isoform 1 (Renal tubular acidosis with deafness)
294.	BAG1	BCL2-associated athanogene
295.	ACHE	acetylcholinesterase (YT blood group)
296.	EGF	epidermal growth factor (beta-urogastrone)
297.	DUSP1	dual specificity phosphatase 1
298.	CASP6	caspase 6, apoptosis-related cysteine protease
299.	THRΒ	thyroid hormone receptor, beta (erythroblastic leukemia viral (v-erb-a) oncogene homolog 2, avian)
300.	BAD	BCL2-antagonist of cell death
301.	STAT6	signal transducer and activator of transcription 6, interleukin-4 induced
302.	ELN	elastin (supravalvular aortic stenosis, Williams-Beuren syndrome)
303.	MAOA	monoamine oxidase A
304.	F8	coagulation factor VIII, procoagulant component (hemophilia A)
305.	ENG	endoglin (Osler-Rendu-Weber syndrome 1)
306.	HSPB1	heat shock 27kD protein 1
307.	HMGCR	3-hydroxy-3-methylglutaryl-Coenzyme A reductase
308.	PIM1	pim-1 oncogene
309.	PON1	paraoxonase 1
310.	AHR	aryl hydrocarbon receptor
311.	ITGB2	integrin, beta 2 (antigen CD18 (p95), lymphocyte function-associated antigen 1; macrophage antigen 1 (mac-1) beta subunit)
312.	PTGS1	prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)
313.	PLCG1	phospholipase C, gamma 1 (formerly subtype 148)
314.	APOC3	apolipoprotein C-III
315.	NRG1	neuregulin 1
316.	CD14	CD14 antigen
317.	IRF1	interferon regulatory factor 1
318.	ALPL	alkaline phosphatase, liver/bone/kidney
319.	ALDOA	aldolase A, fructose-bisphosphate

(continued)

Number	Component	Comments
320.	XPA	xeroderma pigmentosum, complementation group A
321.	PDGFRA	platelet-derived growth factor receptor, alpha polypeptide
322.	IL5	interleukin 5 (colony-stimulating factor, eosinophil)
323.	BMP2	bone morphogenetic protein 2
324.	GSK3A	glycogen synthase kinase 3 alpha
325.	STK11	serine/threonine kinase 11 (Peutz-Jeghers syndrome)
326.	GSK3B	glycogen synthase kinase 3 beta
327.	CRYBB1	crystallin, beta B1
328.	STAT5A	signal transducer and activator of transcription 5A
329.	SCA1	spinocerebellar ataxia 1 (olivopontocerebellar ataxia 1, autosomal dominant, ataxin 1)
330.	RXRA	retinoid X receptor, alpha
331.	NFKBIA	nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha
332.	MMP13	matrix metalloproteinase 13 (collagenase 3)
333.	TSHR	thyroid stimulating hormone receptor
334.	MT2A	metallothionein 2A
335.	TSSC3	tumor suppressing subtransferable candidate 3
336.	RHO	rhodopsin (opsin 2, rod pigment) (retinitis pigmentosa 4, autosomal dominant)
337.	GADD45A	growth arrest and DNA-damage-inducible, alpha
338.	LCAT	lecithin-cholesterol acyltransferase
339.	GSR	glutathione reductase
340.	TOP2A	topoisomerase (DNA) II alpha (170kD)
341.	GPX1	glutathione peroxidase 1
342.	FLT3	fms-related tyrosine kinase 3
343.	CEBPB	CCAAT/enhancer binding protein (C/EBP), beta
344.	TPM1	tropomyosin 1 (alpha)
345.	ABCA4	ATP-binding cassette, sub-family A (ABC1), member 4
346.	KCNH2	potassium voltage-gated channel, subfamily H (eag-related), member 2
347.	HNF4A	hepatocyte nuclear factor 4, alpha
348.	DPYD	dihydropyrimidine dehydrogenase

(continued)

Number	Component	Comments
349.	MADH2	MAD, mothers against decapentaplegic homolog 2 (<i>Drosophila</i>)
350.	AFP	alpha-fetoprotein
351.	TIMP2	tissue inhibitor of metalloproteinase 2
352.	ITK	IL2-inducible T-cell kinase
353.	ABL2	v-abl Abelson murine leukemia viral oncogene homolog 2 (arg, Abelson-related gene)
354.	SCYA4	small inducible cytokine A4
355.	GCGR	glucagon receptor
356.	TCF3	transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47)
357.	MYB	v-myb myeloblastosis viral oncogene homolog (avian)
358.	LTA	lymphotoxin alpha (TNF superfamily, member 1)
359.	LIF	leukemia inhibitory factor (cholinergic differentiation factor)
360.	CYBB	cytochrome b-245, beta polypeptide (chronic granulomatous disease)
361.	CTSL	cathepsin L
362.	BCL2A1	BCL2-related protein A1
363.	TFRC	transferrin receptor (p90, CD71)
364.	RALGDS	ral guanine nucleotide dissociation stimulator
365.	CYP2C8	cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 8
366.	CD38	CD38 antigen (p45)
367.	PRKCZ	protein kinase C, zeta
368.	LAMR1	laminin receptor 1 (67kD, ribosomal protein SA)
369.	IL12A	interleukin 12A (natural killer cell stimulatory factor 1, cytotoxic lymphocyte maturation factor 1, p35)
370.	FGA	fibrinogen, A alpha polypeptide
371.	EEF1A1	eukaryotic translation elongation factor 1 alpha 1
372.	CYP21A2	cytochrome P450, subfamily XXIA (steroid 21-hydroxylase, congenital adrenal hyperplasia), polypeptide 2
373.	CSF2	colony stimulating factor 2 (granulocyte-macrophage)
374.	TNFRSF5	tumor necrosis factor receptor superfamily, member 5
375.	MBP	myelin basic protein

(continued)

Number	Component	Comments
376.	PTK2	PTK2 protein tyrosine kinase 2
377.	KLK3	kallikrein 3, (prostate specific antigen)
378.	GALT	galactose-1-phosphate uridylyltransferase
379.	APEX	APEX nuclease (multifunctional DNA repair enzyme)
380.	EPHB2	EphB2
381.	BIK	BCL2-interacting killer (apoptosis-inducing)
382.	SLC2A1	solute carrier family 2 (facilitated glucose transporter), member 1
383.	IL2RA	interleukin 2 receptor, alpha
384.	IFNGR2	interferon gamma receptor 2 (interferon gamma transducer 1)
385.	AXL	AXL receptor tyrosine kinase
386.	ADRB1	adrenergic, beta-1-, receptor
387.	RAD51	RAD51 homolog (RecA homolog, <i>E. coli</i>) (<i>S. cerevisiae</i>)
388.	GJA1	gap junction protein, alpha 1, 43kD (connexin 43)
389.	EWSR1	Ewing sarcoma breakpoint region 1
390.	CCR2	chemokine (C-C motif) receptor 2
391.	RELA	v-rel reticuloendotheliosis viral oncogene homolog A, nuclear factor of kappa light polypeptide gene enhancer in B-cells 3, p65 (avian)
392.	CTNNA1	catenin (cadherin-associated protein), alpha 1 (102kD)
393.	MY07A	myosin VIIA (Usher syndrome 1B (autosomal recessive, severe))
394.	F3	coagulation factor III (thromboplastin, tissue factor)
395.	EPHX1	epoxide hydrolase 1, microsomal (xenobiotic)
396.	CRK	v-crk sarcoma virus CT10 oncogene homolog (avian)
397.	EN01	enolase 1, (alpha)
398.	TGFBR1	transforming growth factor, beta receptor I (activin A receptor type II-like kinase, 53kD)
399.	RAC1	ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding protein Rac1)
400.	ANPEP	alanyl (membrane) aminopeptidase (aminopeptidase N, aminopeptidase M, microsomal aminopeptidase, CD13, p150)

[0141] A kit and/or method according to the invention may be used to detect infectious diseases. Some infectious diseases are life threatening and can appear in combination with other infections. Thus, the sooner they can be detected

and characterised, the sooner an appropriate therapy can be established which is better for the patient. A kit and/or method as disclosed above can be used to detect said infectious agents. Components which may be detected according to the kit and/or method are those which form part of the infectious agent and/or are produced by the infectious agent. Viruses in diseased individuals detectable according to the kit and/or method include, but are not limited to HCV, HIV, 5 HBV, HTLV, HPV (see also oncology). Bacteria in diseased individuals detectable according to the kit and/or method include, but are not limited to mycobacteria, syphilis, *Staphylococcus aureus* (screening of MRSA).

5 [0142] A kit and/or method according to the invention may be used to detect neurodegenerative diseases. Components which may be detected are those involved in degenerative diseases and include, but are not limited to beta-amyloids (Alzheimer's disease), hTAU, phosphoTAU and APOE.

10 [0143] A kit and/or method according to the invention may be used to detect prion-related diseases. Diseases associated with prions include Kreutzfeld Jacob disease and BSE.

[0144] A kit and/or method according to the invention may be used to detect diseases related to autoimmunity. Components which may be detected are those involved in autoimmunity include, but are not limited to ANA, Jo-1, Myeloperoxidase, RNP, Scl-70, Sm, SS-A.

15 [0145] A kit and/or method according to the invention may be used to detect diseases related to allergy. Components which may be detected are those involved in allergy and include, but are not limited to IgE, IgG-subclasses and circulating antibodies.

[0146] A kit and/or method according to the invention may be used in the field of genomics to detect susceptibility to disease, possibility of passing conditions to offspring, single nucleotide polymorphisms etc. Examples of fields in which 20 a kit and/or method of the invention apply include, but are not limited to HLA typing, p53 polymorphism (SNP) related to the sensitivity of developing a cervix carcinoma after an HPV 16 infection, hypertension, detection of polymorphism in relation to the susceptibility for osteoporosis, detection of mutations in Factor V (Leiden), detection of the genetic susceptibility for SIDS (cot death), hereditary: paternity tests, etc., detection of micro satellite instability, detection of the success rate of therapy related to cessation of smoking, detection of disturbances in the metabolism of lipids including 25 cholesterol (HDL, LDL, VLDL and their receptors) in relationship to cardiovascular diseases such as atheromathosis, detection of genomic defects related to obesitas, detection of genomic defects related to diabetes, detection of mutations associated with drug resistance (to HIV, etc.), screening and detection of systic fibrosis (CFTR mutations), detection of mutations in the mitochondrial genome related to a number of diseases as: neurogenic muscular weakness, retinitis pigmentosa, ocular myopathy, etc.

30 [0147] A kit and/or method according to the invention may be used in the fields related to environmental testing. Many applications are related to water where it is important to have a technology which is sensitive enough to detect very small amounts of contaminants or unwanted compounds in reasonably economical manner. Examples of environmental tests include:

35 - checking (monitoring) of yeast infections in swimming pool water
 - monitoring of biological pollution in general
 - biological contaminants in potable water (amoebae, coliform bacteria, etc.).

[0148] In addition to water testing, the environmental testing for genetically modified organisms may be performed 40 according to a kit and/or method of the present invention. Genetically Modified Organisms can be detected, or samples screened for the absence of. Checking for possible modifications is sometimes difficult, however, a sensitive technique such as that provided by the present method is suitable for such a purpose.

[0149] A kit and/or method according to the invention may be used to detect the infection of food. Inspection of all 45 places and objects related to food needs sensitive methods, and kit and/or method of the present invention provide the required sensitivity. Furthermore, a kit and/or method of the present invention can be performed and the results obtained at the site at which the inspection takes place, so obviating the need to send samples to a lab. Thus, steps can be taken immediately if necessary. Examples of the agents that may be detected include Listeria, Salmonella, prions (for BSE). Molecules which may be detected assay are those which form part of the agent and/or are produced by the agent.

[0150] A kit and/or method of the present invention may be applied in standard biochemical detection protocols. All 50 the existing types of blotting techniques show an enhancement in sensitivity using the method disclosed herein, without the requirement for radioisotopes or chemiluminescent detection such as photographic plates, or phosphor screens. It is also possible to use the method in combination with image analysis. Examples of blotting protocols that may use methods of the present invention include but are not limited to Western blotting, Northern blotting, Southern blotting, vacuum blotting, contact blotting, reversed line blot and related techniques, dot blotting, micro-arrays, macro-arrays.

55 [0151] Another embodiment of the present invention is a use of a method or kit as described herein for the quantitative and/or qualitative detection of components in a sample. Another embodiment of the present invention is a use of kit as described herein for imaging components in a system by magnetic resonance.

Staining of microscopy slides

[0152] Another embodiment of the present invention is a method for staining sections of cells and/or tissues suitable for visualisation using microscopy. Types of microscopy may be any, and include, but are not limited to light microscopy, 5 tunneling electron microscopy, scanning electron microscopy, transmission electron microscopy.

[0153] According to one aspect of the invention, a method for staining components in cell and/or tissue sections, said staining suitable for visualisation using microscopy comprises the following steps:

- 10 A) incubating section with one or more biotinylated probes directed against a component,
- B) incubating section with streptavidin-metal particle complex,
- C) incubating section with conjugate comprising:
 - one or more biotins,
 - one or more polymers, and
 - metal particles bound to said polymer, and
- D) optionally incubating the section with metal enhancement reagent.

[0154] Biotinylated probes, strepavidin-metal particle complex, conjugate and the kinds of metal particles are already 20 described above. The introduction of other steps into the method, such as wash steps, for example, may be known by the skilled artisan practicing in the field of immunohistochemistry. Preferably, a wash is performed after every step. Examples of wash buffers are described above. The "metal enhancement reagent" of step D) is also described above.

[0155] A kit for staining sections of cells and/or tissues suitable for visualisation using microscopy may comprising 25 one or more of the following:

- streptavidin-metal particle complex
- conjugate
- biotinylated probe
- metal enhancement reagent
- 30 - reagents for biotinylation

[0156] A kit for staining sections allows a skilled artisan to perform one or more steps of the method disclosed herein, in a convenient manner. The kit may allow a method of the present invention to be performed without the need to measure or determine the concentrations of reagents, so enabling a fast and reproducible staining of sections.

[0157] The kit for staining sections enables the skilled person to perform one or more of the methods disclosed herein. 35 The kit may comprise one or more additional containers in which reagents are present enabling the skilled person to perform the complete method. Alternatively, the kit may comprise a minimum number of containers, such as only streptavidin-metal particle complex, for example, that enables a skilled person to perform the method disclosed herein.

[0158] The kit may contain instructions for use. The instructions describe a method of the invention as disclosed herein.

[0159] A method of the present invention for staining sections of cells may equally well be performed on any cell or 40 tissue in the applications of flow cytometry and *in situ* hybridisation, wherein the visualisation of cells and tissues is necessary. Due to the sensitivity of the method as disclosed herein, target antigens (proteins and other substances) can be visualised in tissues and cells with antibodies and, using *in situ* hybridization, they can be visualised by use of nucleic acid probes.

45 **EXAMPLES**

Section 1: Materials and methods

50 **Oligonucleotides**

[0160]

Target:	5' GGATTATTGTTAAATATTGATAAGGAT 3'
55 Visualisation oligo:	5' ATCCTTATCAATATT 3'
Oligo op drager:	5' TAACAATAATCC 3'

[0161] The above mentioned oligonucleotides are derived from the Anthrax lethal factor genome.

Nylon or nitrocellulose coated slides

5 [0162] Coated slides such as Nytran coated slides, nitrocellulose coated slides were purchased from Schleicher and Schuell and printed with DNA capturing oligonucleotides using a MICROCAST micro-arrayer. Modified DNA oligonucleotides were custom made by Eurogentec (Belgium) and in varying concentrations dissolved in printing buffer (6x SSC).

10 Micro-arrays were manufactured by printing varying oligonucleotide concentrations ranging from 0.001 μ M to 20 μ M on the coated glass slide. Negative controls consisted of printing buffer without DNA oligonucleotides and printing buffer with a DNA oligonucleotide complementary to a non-related sequence in the same concentration as the capturing oligonucleotide of interest. After drying during 30 minutes at room temperature, the slides were baked at 80°C for 30 minutes. The DNA printed Nytran coated slides were cross linked using UV radiation according to previously described protocols.

15 Slides were stored dust-free at 4°C until further analysis.

Silane coated slides

20 [0163] Silane coated slides were purchased from Schleicher and Schuell and printed with DNA oligonucleotides using a MICROCAST micro-arrayer.

[0164] DNA oligonucleotides were custom made by Eurogentec (Belgium) and in varying concentrations dissolved in printing buffer. Silane coated slides and modified oligonucleotides were activated according to previously described protocols.

25 [0165] Micro-arrays were manufactured by printing varying oligonucleotide concentrations ranging from 0.001 μ M to 20 μ M on the activated silane coated glass slide. After drying for 30 minutes at room temperature, the printed slides were stored dust-free at 4°C.

Classical glass slides

30 [0166] Classical microscopical glass slides were washed with twice distilled water followed by immersion in a 10 % NaOH solution at room temperature, and followed by an ultrasound treatment for 30 minutes. After several washes in running tap water, slides were washed several times with twice distilled water. Afterwards the slides were dried at 80 °C.

[0167] Modified oligonucleotides were activated and coupled with aminosilane according to previously described protocols (Kumar et al. Silanized nucleic acids: a general platform for DNA immobilization. Nucleic acids res 2000; 28: p71.).

35 The silanized oligonucleotides were dissolved in printing buffer (50% DMSO,) and printed as described above.

Printing of the micro-arrays

40 [0168] Micro-arrays were printed with each concentration of capturing oligonucleotides and the above described appropriate negative controls, a total of six times.

Section 2: Experiments to compare methods of detection using gold and enzyme visualisations in combination with polymer amplification and other technologies

45 **Part 1 - Visualization experiments of labeled oligonucleotides in the above described solid assays**

Experiment 1 - part 1: visualization of labeled oligonucleotides using streptavidin

50 [0169] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μ M to 20 μ M were spotted six times using biotinylated probes. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use. Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein. Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

55 [0170] Slides were incubated with streptavidin/alkaline phosphatase (concentration 1/1000 in PBS/protein buffer) (Roche Germany) for 60 minutes followed by three washes with PBS/protein buffer at room temperature. The alkaline phosphatase reaction was developed by incubating the slides with naphthol substrate in appropriate buffer (Dako, Denmark) for 30 minutes at room temperature.

Experiment 2 - part 1: visualization of labeled oligonucleotides using streptavidin labeled with gold particles

[0171] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μM to 20 μM were spotted six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use.

5 Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein for 5 minutes).

Slides were incubated with streptavidin/gold 0.8 nm (concentration 1/50 in washing buffer) or 6 nm (concentration 1/20 in washing buffer) (Sigma, U.S.A.) for 120 minutes followed by six washes with washing buffer at room temperature.

10 [0172] Slides were rinsed three times for five minutes with PBS, followed by distilled water.

The gold particles were visualized by metal enhancement (Sigma U.S.A.) for 15 minutes.

Experiment 3 - part 1: visualization of labeled oligonucleotides using monoclonal antibodies labeled with gold particles

15 [0173] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μM to 20 μM were spotted in six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use.

Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution during 30 minutes at room temperature.

20 Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented - with 0.2 % protein) for 5 minutes.

[0174] Slides were incubated with monoclonal antibody/gold 0.8 nm (concentration 1/50 in washing buffer), 6 nm (concentration 1/20 in washing buffer) or 30nm for 120 minutes followed by six washes with washing buffer at room temperature.

Slides were rinsed three times for five minutes with PBS, followed by distilled water.

25 The gold particles were visualized by metal enhancement during 15 minutes.

Experiment 4 - part 1: visualization of labeled oligonucleotides using polyclonal antibodies labeled with gold particles

30 [0175] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μM to 20 μM were spotted six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use.

Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes.

35 Slides were incubated with monoclonal antibody/gold 0.8 nm (concentration 1/50 in washing buffer) or 6 nm (concentration 1/20 in washing buffer) for 120 minutes followed by six washes with washing buffer at room temperature.

Slides were rinsed three times for five minutes with PBS, followed by distilled water.

The gold particles were visualized by metal enhancement during 15 minutes.

40 Experiment 5 - part 1: visualization of labeled oligonucleotides using streptavidin-gold, biotinylated monoclonal and polyclonal antibodies followed by streptavidin labeled with gold

[0176] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μM to 20 μM were spotted six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use.

45 Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes and incubated with the same washing buffer.

50 Slides were incubated with streptavidin labeled with gold particles ranging from 0.8 nm to 40 nm during 30 minutes followed by six washes with washing buffer at room temperature.

[0177] Slides were incubated with biotinylated monoclonal or biotinylated polyclonal antibody labeled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer at room temperature.

Slides were incubated with streptavidin labeled with gold particles ranging from 0.8 nm to 40 nm during 30 minutes followed by six washes with washing buffer at room temperature

55

Experiment 6 - part 1: visualization of labeled oligonucleotides using gold labeled streptavidin followed by biotinylated albumin and gold particles

5 [0178] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μ M to 20 μ M were spotted six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use.
Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.
Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.
Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) during 5 minutes and incubated with the same washing buffer.
10 Slides were incubated with streptavidin labeled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer at room temperature.
Slides were incubated with albumin coated with numerous biotin molecules and labeled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer followed by distilled water.
The gold particles were visualized by metal enhancement for 15 minutes.
15

Experiment 7 - part 1: visualization of labeled oligonucleotides using 200 nm supermagnetic particles coated with streptavidin followed by biotinylated albumin and gold particles

20 [0179] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μ M to 20 μ M were spotted six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use.
Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.
Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.
Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes and incubated with the same washing buffer.
25 [0180] Slides were incubated with 200 nm nanoparticles coated with streptavidin followed by six washes with washing buffer at room temperature.
Slides were incubated with albumin coated with numerous biotin molecules and labeled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer followed by distilled water.
The gold particles were visualized by metal enhancement for 15 minutes.
30

Experiment 8 - part 1: visualization of labeled oligonucleotides using 200 nm particles coated with streptavidin, followed by polymer and gold particles.

35 [0181] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μ M to 20 μ M were spotted six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use.
Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.
Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.
Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes and incubated with the same washing buffer.
40 Slides were incubated with 200 nm nanoparticles coated with streptavidin followed by six washes with washing buffer at room temperature.
Slides were incubated with dextran polymer or poly-L-lysine polymer coated with numerous biotin molecules and labeled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer followed by distilled water.
45 The gold particles were visualized by metal enhancement during 15 minutes.

Part 2: Hybridization experiments of labeled oligonucleotides attached at the above described solid assays

Experiment 2.1 - part 2: visualization of labeled oligonucleotides using streptavidin

50 [0182] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μ M to 20 μ M were spotted six times including adequate positive and negative controls. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use.
The slides were prehybridized with hybridization mixture supplemented with sonicated herring sperm DNA (150 μ g/5 ml hybridization mixture) for 2 hours at room temperature.
55 [0183] Hybridization assay was set up using target DNA consisting of labeled oligonucleotide at a concentration of 250 ng/ml hybridization mixture. Hybridization was carried out overnight at 37°C.
Slides were washed twice with 2x SSC at room temperature.

Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

Slides were incubated with streptavidin/alkaline phosphatase (concentration 1/1000 in PBS/protein buffer) for 60 minutes followed by three washes with PBS/protein buffer at room temperature.

5 The alkaline phosphatase reaction was developed by incubating the slides with naphthol substrate in appropriate buffer for 30 minutes at room temperature.

Experiment 2.2 - part 2: visualization of labeled oligonucleotides using streptavidin labeled with gold particles

10 [0184] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μ M to 20 μ M were spotted six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use.

[0185] The slides were prehybridized with hybridization mixture supplemented with sonicated herring sperm DNA (150 μ g/5 ml hybridization mixture) for 2 hours at room temperature.

15 Hybridization assay was set up using target DNA consisting of labeled oligonucleotide in a concentration of 250 ng/ml hybridization mixture. Hybridization was carried out overnight at 37°C.

Slides were washed twice with 2x SSC at room temperature.

Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) during 5 minutes.

20 Slides were incubated with streptavidin/gold 0.8 nm (concentration 1/50 in washing buffer) or 6 nm (concentration 1/20 in washing buffer) for 120 minutes followed by six washes with washing buffer at room temperature.

Slides were rinsed three times during five minutes with PBS, followed by distilled water.

[0186] The gold particles were visualized by metal enhancement for 15 minutes.

25 **Experiment 3 - part 2: visualization of labeled oligonucleotides using monoclonal antibodies labeled with gold particles**

[0187] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μ M to 20 μ M were spotted in six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use.

30 The slides were prehybridized with hybridization mixture supplemented with sonicated herring sperm DNA (150 μ g/5 ml hybridization mixture) for 2 hours at room temperature.

Hybridization assay was set up using target DNA consisting of labeled oligonucleotide at a concentration of 250 ng/ml hybridization mixture. Hybridization was carried out overnight at 37°C.

Slides were washed twice with 2x SSC at room temperature

35 Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes.

Slides were incubated with monoclonal antibody/gold 0.8 nm (concentration 1/50 in washing buffer) or 6 nm (concentration 1/20 in washing buffer), or 30nm for 120 minutes followed by six washes with washing buffer at room temperature.

40 Slides were rinsed three times for five minutes with PBS, followed by distilled water.

The gold particles were visualized by metal enhancement for 15 minutes.

Experiment 4- part 2: visualization of labeled oligonucleotides using polyclonal antibodies labeled with gold particles

45 [0188] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μ M to 20 μ M were spotted six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use.

The slides were prehybridized with hybridization mixture supplemented with sonicated herring sperm DNA (150 μ g/5 ml hybridization mixture) for 2 hours at room temperature.

50 Hybridization assay was set up using target DNA consisting of labeled oligonucleotide in a concentration of 250 ng/ml hybridization mixture. Hybridization was carried out overnight at 37°C.

[0189] Slides were washed twice with 2x SSC at room temperature

Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

55 Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes.

Slides were incubated with monoclonal antibody/gold 0.8 nm (concentration 1/50 in washing buffer) or 6 nm (concentration 1/20 in washing buffer) for 120 minutes followed by six washes with washing buffer at room temperature.

Slides were rinsed three times for five minutes with PBS, followed by distilled water.

The gold particles were visualized by metal enhancement for 15 minutes.

Experiment 5 - part 2: visualization of labeled oligonucleotides using streptavidin-gold, biotinylated monoclonal and polyclonal antibodies followed by streptavidin labeled with gold

5

[0190] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μ M to 20 μ M were spotted six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use. The slides were prehybridized with hybridization mixture supplemented with sonicated herring sperm DNA (150 μ g/5 ml hybridization mixture) for 2 hours at room temperature. Hybridization assay was set up using target DNA consisting of labeled oligonucleotide in a concentration of 250 ng/ml hybridization mixture. Hybridization was carried out overnight at 37°C. Slides were washed twice with 2x SSC at room temperature. Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein. Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature. Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes and incubated with the same washing buffer. Slides were incubated with streptavidin labeled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer at room temperature. Slides were incubated with biotinylated monoclonal or biotinylated polyclonal antibody labeled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer at room temperature. [0191] Slides were incubated with streptavidin labeled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer at room temperature.

Experiment 6 - part 2: visualization of labeled oligonucleotides using gold labeled streptavidin followed by biotinylated albumin and gold particles

[0192] The slides were prehybridized with hybridization mixture supplemented with sonicated herring sperm DNA (150 μ g/5 ml hybridization mixture) for 2 hours at room temperature. Hybridization assay was set up using target DNA consisting of labeled oligonucleotide in a concentration of 250 ng/ml hybridization mixture. Hybridization was carried out overnight at 37°C. Slides were washed twice with 2x SSC at room temperature. Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μ M to 20 μ M were spotted six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use. Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein. Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature. Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes and incubated with the same washing buffer. Slides were incubated with streptavidin labeled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer at room temperature. Slides were incubated with albumin coated with numerous biotin molecules and labeled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer followed by distilled water. The gold particles were visualized by metal enhancement for 15 minutes.

Experiment 7 - part 2: visualization of labeled oligonucleotides using 200 nm supermagnetic particles coated with streptavidin followed by biotinylated albumin and gold particles

[0193] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μ M to 20 μ M were spotted six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use. The slides were prehybridized with hybridization mixture supplemented with sonicated herring sperm DNA (150 μ g/5 ml hybridization mixture) for 2 hours at room temperature. [0194] Hybridization assay was set up using target DNA consisting of labeled oligonucleotide in a concentration of 250 ng/ml hybridization mixture. Hybridization was carried out overnight at 37°C. Slides were washed twice with 2x SSC at room temperature. Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein. Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature. Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes and incubated with the same washing buffer. Slides were incubated with 200 nm nanoparticles coated with streptavidin followed by six washes with washing buffer

at room temperature.

Slides were incubated with albumin coated with numerous biotin molecules and labeled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer followed by distilled water.

The gold particles were visualized by metal enhancement for 15 minutes.

5

Experiment 8 - part 2: visualization of labeled oligonucleotides using 200 nm particles coated with streptavidin, followed by polymer and gold particles.

[0195] Micro-arrays were printed as described previously. All concentrations ranging from 0.001 μ M to 20 μ M were spotted six times. Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use.

The slides were prehybridized with hybridization mixture supplemented with sonicated herring sperm DNA (150 μ g/5 ml hybridization mixture) for 2 hours at room temperature.

Hybridization assay was set up using target DNA consisting of labeled oligonucleotide in a concentration of 250 ng/ml hybridization mixture. Hybridization was carried out overnight at 37°C.

15

Slides were washed twice with 2x SSC at room temperature

Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes and incubated with the same washing buffer.

20

[0196] Slides were incubated with 200 nm nanoparticles coated with streptavidin followed by six washes with washing buffer at room temperature.

Slides were incubated with dextran polymer or poly-L-lysine polymer coated with numerous biotin molecules and labeled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer followed by distilled water.

25

The gold particles were visualized by metal enhancement for 15 minutes.

Results and discussion

Results of experiments without signal amplification:

30

Experiment 1 - Visualization with streptavidin-enzyme

[0197] Hybridization was visualized as deep red or dark brown spots according to the used enzyme and substrate. The spots were easy discernible at the white background of the slide. Background staining was not present. Visualization was achieved with spotted molecular probe concentration ranging from 0.2 mM to 0.02 mM.

Experiment 2 - Visualization with streptavidin gold 0.8 nm and 6 nm

40

[0198] Hybridization was visualized as deep black grey spots according to the used metal enhancement. The spots were easy discernible at the white background of the slide. Background staining was not present. Visualization was achieved with spotted molecular probe concentration ranging from 0.2 mM to 0.02 mM.

Experiment 3 - Visualization with monoclonal mouse antibodies with gold 0.8 nm and 6 nm

45

[0199] Hybridization was visualized as deep black spots according to the used metal enhancement. The spots were easy discernible at the white background of the slide. Background staining was not present. Visualization was achieved with spotted molecular probe concentration ranging from 0.2 mM to 0.002 mM. However the signal was stronger with the 6 nm gold compared to the 0.8 nm gold and sharper than with the streptavidin-gold method. In comparison with the polyclonal antibodies the signal was slightly sharper.

50

Experiment 3 - Visualization with monoclonal mouse antibodies with gold 30 nm

[0200] Hybridization was faintly visualized as light rosa spots only at the highest spot concentration of 0.2 mM. Metal enhancement did not yield significant signal strengthening. Background staining was considerable.

55

Experiment 4 - Visualization with polyclonal goat antibodies with gold 0.8 nm and 6 nm

[0201] Hybridization was visualized as deep black spots according to the used metal enhancement. The spots

were easy discernible at the white background of the slide. Background staining was not presented. Visualization was achieved with spotted molecular probe concentration ranging from 0.2 mM to 0.002 mM. However the signal was stronger with the 6 nm gold compared to the 0.8 nm gold and sharper than with the streptavidin-gold method.

5 **Results of experiments with signal amplification:**

Experiment 5 - Visualization with streptavidin/gold-biotinylated monoclonal and polyclonal antibodies followed by streptavidin labeled with gold.

10 [0202] Hybridization was visualized as deep black spots. The spots were easy discernible at the white background of the slide. Background staining was slight. Visualization was achieved with spotted molecular probe concentration ranging from 0.1 mM to 0.0001 mM.

15 **Experiment 6 - Visualization with gold labeled streptavidin (gold 0.8 nm, 6 nm and 30 nm) followed by biotinylated albumin and gold partikels 0.8, 6 nm and 30 nm**

20 [0203] Hybridization was visualized as deep black spots according to the used metal enhancement.strate. The spots were easy discernible at the white background of the slide. Background staining was very slight. Visualization was achieved with spotted molecular probe concentration ranging from 0.1 mM to 0.0001 mM. However the signal was stronger with the 0.8 nm gold compared to the 6 nm gold and sharper than with the streptavidin-enzym method. The 30 nm gold particles gave a slight rosa reaction barely discernible with the naked eye.

Experiment 7 - Visualization with superparamagnetic particle 200 nm-streptavidin/gold-albumin/gold/biotin

25 [0204] Hybridization was visualized as deep grey to black brown spots. The spots were easy discernible at the white background of the slide. Background staining was low to moderately. Visualization was achieved with spotted molecular probe concentration ranging from 0.2- mM to 0.0002 mM.

Experiment 8 - Visualization with streptavidin gold 0.8 nm and 6 nm-polymer/gold

30 [0205] Hybridization was visualized as deep black grey spots according to the used metal enhancement. The spots were easy discernible at the white background of the slide. Background staining was absent. Visualization was achieved with spotted molecular probe concentration ranging from 0.2 mM to 0.0002 mM. However the signal was stronger with the 6 nm gold compared to the 0.8 nm gold and sharper than with the streptavidin-gold method.

35 **Section 3: Detection and subtyping of HPV DNA**

40 [0206] Micro-arrays were printed as described previously using specific oligonucleotides detecting HPV 16, HPV18, HPV 31, HPV 33, HPV 35, HPV 52 and HPV 58. The oligonucleotides were dissolved in printing buffer resulting in an end concentration of 10 μ M and were spotted six times including adequate positive and negative controls using a Microcast manual arrayer.

45 This results in a micro-array with 7 seven rows, each row consisting of six identical spots, representing the seven above described HPV types. The negative controls consisted of printing buffer without DNA and a second negative control consisted of an oligonucleotide coding for a non-related gene segment and were printed as two rows consisting of six spots where one row consisted out of printing buffer without DNA and another row consisted of non-related DNA oligonucleotide.

[0207] The positive control consisted of an equimolar mixture of the above described HPV type specific oligonucleotides printed in one row consisting of six identical spots.

After printing the micro-arrays were air dried at room temperature for 15 minutes.

50 Micro-arrays were baked at 80°C for 30 minutes and stored dust-free at 4°C until use.

[0208] The slides were prehybridized with hybrimix hybridization buffer (Sigma, USA) supplemented with sonicated herring sperm DNA (150 μ g/5 ml hybridization mixture) (Sigma, USA) for 2 hours at room temperature.

Hybridization with PCR labeled amplification product

55 [0209] Hybridization assay was set up using PCR amplified HPV DNA. During the PCR reaction the amplification product was labeled using a biotin labeled primer. In another experiment the PCR was set up with two unlabeled primers.

Ten microliter of the PCR amplification product was denatured with 10 µl denaturation solution (NAOH/EDTA). The denatured DNA solution was added to 2 ml of hybridization mixture. The micro-arrays were covered with a cover slip and hybridized overnight at 37°C in a humid chamber.

Slides were washed twice with 2x SSC supplemented with 0.1 % SDS at room temperature.

5 Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

The hybridization of the biotin labeled PCR product was revealed using one of the methods described above.

Visualisation with streptavidin-alkaline phosphatase

10 [0210] Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

Slides were incubated with streptavidin/alkaline phosphatase (concentration 1/1000 in PBS/protein buffer) for 60 minutes followed by three washes with PBS/protein buffer at room temperature.

The alkaline phosphatase reaction was developed by incubating the slides with naphthol substrate in appropriate buffer for 30 minutes at room temperature.

15

Visualisation with streptavidin- gold

[0211] Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

20 Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes.

[0212] Slides were incubated with streptavidin/gold 0.8 nm (concentration 1/50 in washing buffer) or 6 nm (concentration 1/20 in washing buffer) for 120 minutes followed by six washes with washing buffer at room temperature.

Slides were rinsed three times for five minutes with PBS.

The gold particles were visualized by metal enhancement for 15 minutes.

25

Visualisation with mono-or polyclonal anti-biotin antibody

[0213] Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

30 Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes.

Slides were incubated with monoclonal or polyclonal antibody/gold 0.8 nm (concentration 1/50 in washing buffer) or 6 nm (concentration 1/20 in washing buffer) for 120 minutes followed by six washes with washing buffer at room temperature.

Slides were rinsed three times for five minutes with PBS.

The gold particles were visualized by metal enhancement for 15 minutes.

35

Visualisation using streptavidin-gold followed by signal amplification with biotinylated polymer technology

[0214] Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

40 Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes and incubated with the same washing buffer.

Slides were incubated with streptavidin labeled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer at room temperature.

45 Slides were incubated with dextran polymer or poly-L-lysine polymer coated with numerous biotin molecules for 30 minutes followed by six washes with washing buffer.

Slides were incubated with monoclonal or polyclonal anti-biotin antibody or streptavidin labeled with gold particles ranging from 0.8 nm to 40 nm for 60 minutes followed by six washes with washing buffer at room temperature.

Slides were rinsed three times for five minutes with PBS.

The gold particles were visualized by metal enhancement for 15 minutes.

50

Hybridization with unlabeled PCR amplification product, visualization using an intercalating agent, signal amplification with polymer technology and gold.

[0215] Hybridization assay was set up using PCR amplified HPV DNA.

55 In this part of the experiment the PCR was set up with two unlabeled primers.

[0216] Ten microliter of the PCR amplification product was denatured with 10 µl denaturation solution (NAOH/EDTA).

The denatured DNA solution was added to 2 ml of hybridization mixture. The micro-arrays were covered with a cover slip and hybridized overnight at 37°C in a humid chamber.

Slides were washed twice with 2x SSC supplemented with 0.1 % SDS at room temperature.

Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

The hybridization of the unlabeled PCR product with its capture oligonucleotide at the micro-array was revealed using an intercalating agent, type DAPI (4',6-Diamidino-2-phenylindole dihydrochloride) that was coupled with streptavidin.

5 [0217] Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes and incubated with the same washing buffer.

10 Slides were incubated with dapi or doxorubicine conjugated with streptavidin labelled with gold particles ranging from 0.8 nm to 40 nm for 60 minutes followed by six washes with washing buffer at room temperature.

Slides were incubated with biotinylated albumin/gold or poly-L-lysine polymer coated with biotin molecules for 30 minutes followed by six washes with washing buffer.

Slides were incubated with streptavidin labeled with gold particles ranging from 0.8 nm to 40 nm for 60 minutes followed by six washes with washing buffer at room temperature

15 Slides were rinsed three times for five minutes with PBS.

The gold particles were visualized by metal enhancement for 15 minutes.

Results and discussion

20 [0218] Hybridized micro-arrays showed areas with very sharp black or red coloured spots in some areas depending on the used substrate. Other areas did not show any signal. Background signal was completely absent.

Hybridization was revealed as easy discernible bright spots coloured deep red when using the alkaline phosphatase technique for visualization or as deep grey to black spots when using gold-metal enhancement technology. The results were easily evaluated with the naked eye. The best results were obtained with gold labeled antibodies used in a polymer amplification technique and streptavidin-gold-albumin method.

25 Negative controls did not show any sign of positivity. The positive control was strongly positive. In one experiment the presence of HPV 16 was revealed and in another experiment the presence of HPV 18 was highlighted. Cross-hybridization with other molecular probes was not noted. Samples without HPV DNA did not give a signal at the micro-array.

30 **Section 4: Application of immunohistochemistry: visualization of *in situ* of monoclonal antibodies using gold labeled monoclonal and polyclonal antibodies in a polymer enhanced amplification technique**

[0219] Sections of 5 μ m were cut from paraffin embedded formalin fixed tissue of squamous lung carcinoma and adhered to poly-L-lysine coated glass slides, dried at 55°C overnight and stored dust-free at room temperature. The 35 sections were deparaffinized in two rinses of xylene substitute, followed by rehydratation in an descending series of alcohols down to deionized water. Slides were washed twice with PBS (pH 7.4) and incubated with anti-ema (epithelial membrane antigen) monoclonal mouse antibody (Dakopatts Denmark) according to the instructions of the manufacturer).

Slides were washed twice with PBS (pH 7.4) supplemented with 3 % protein.

Slides were incubated with the same PBS/protein buffer solution for 30 minutes at room temperature.

40 Slides were washed twice with special washing buffer (PBS pH 7.4 supplemented with 0.2 % protein) for 5 minutes and incubated with the same washing buffer.

Slides were incubated with biotinylated monoclonal or polyclonal anti-mouse antibody labelled with gold particles ranging from 0.8 nm to 40 nm for 60 minutes followed by six washes with washing buffer at room temperature.

[0220] Slides were incubated with streptavidin polymer (dextran or poly-L-lysine) coated with gold particles for 30 45 minutes followed by six washes with washing buffer.

Optional slides were incubated with biotinylated albumin labelled with gold particles ranging from 0.8 nm to 40 nm for 30 minutes followed by six washes with washing buffer at room temperature

Slides were rinsed three times for five minutes with PBS, followed by distilled water.

The gold particles were visualized by metal enhancement for 15 minutes.

50 [0221] The results showed clear and sharp staining with excellent contrast.

Claims

55 1. Method for quantitatively and/or qualitatively detecting one or more components in a sample, each component capable of binding to a probe, comprising steps in the following order:

(a) applying one or more samples onto a solid support,

(b) contacting solid support with one or more biotin-labeled probes,
(c) contacting solid support with streptavidin-metal particle complex,
(d) contacting solid support with conjugate comprising:

5 - one or more biotins,
 - one of more polymers, and
 - metal particles bound to said polymer,

10 (e) optionally contacting the solid support with metal enhancement reagent, and
 (f) reading the solid support to quantitatively and/or qualitatively detect said component.

2. A method according to claim 1 wherein step (a) is replaced by:

15 (a) applying one or more probes onto solid support,
 and step (b) is replaced by:
 (b) contacting solid support with biotin-labelled sample.

3. A method according to claim 1 wherein step (a) is preceded by:

20 (a0) applying one or more probes onto solid support.

4. A method according to claims 2 or 3 wherein the solid support is supplied with probe pre-applied, and step (a) of
claim 2 or step (a0) of claim 3 is not performed by the user.

25 5. A method according to any of claims 1 to 4 wherein the reading of step (f) comprises the use of a colour chart.

6. A method according to any of claims 1 to 4 wherein the reading of step (f) comprises a use of a device suitable for
detecting changes in conductance and/or current across the solid support.

30 7. A method according to any of claims 1 to 4 wherein the reading of step (f) comprises a use of a device suitable for
detecting changes in magnetic field on the solid support.

8. A method according to any of claims 1 to 4 wherein the reading of step (f) comprises a use of a device suitable for
detecting changes in surface plasmon resonance on the solid support.

35 9. A method according to any of claims 1 to 8 wherein the metal enhancement reagent of step (e) is a silver enhancement
reagent

40 10. A kit for quantitatively and/or qualitatively detecting one or more components in a sample, each component capable
of binding to a probe, comprising:

- streptavidin-metal particle complex,
- solid support, and
- conjugate comprising:

45 - biotin,
 - polymer, and
 - metal particles bound to said polymer.

50 11. A kit according to claim 10 further comprising:

- one or more probes.

12. A kit according to claim 11 wherein said probes are biotinylated.

55 13. A kit according to any of claims 10 to 12 wherein said solid support preloaded with one or more probes.

14. A method according to any of claims 1 to 9, or a kit according to any of claims 10 to 13 wherein the polymer of a

conjugate is a biologically inert polymer, capable of binding to one or more metal particles.

15. A method or kit according to claim 14, wherein a polymer is any of albumin or dextran.
- 5 16. A method according to any of claims 1 to 9, 14 or 15, or a kit according to any of claims 10 to 13 wherein conjugate comprises one or more particles of gold, silver, iron, nickel, gadolinium, lead, uranium, caesium, platinum, rhodium, technetium, tellurium, selenium, silicon, silicium, copper, tin, rhenium, europium, aluminium, germanium, chromium, cadmium, niobium, titanium, magnesium, manganese, molybdenum, antimony, americium, lithium, and/or wolfram.
- 10 17. A method according to any of claims 1 to 9, 14 or 15, or a kit according to any of claims 10 to 13 wherein conjugate comprises one or more gold particles.
- 15 18. A method according to any of claims 1 to 9, 14 or 15, or a kit according to any of claims 10 to 13 wherein a conjugate comprises one or more silver particles.
19. A method according to any of claims 1 to 9, 14 to 18, or a kit according to any of claims 10 to 18 wherein the metal particles of conjugate have a diameter between 0.6 to 40 nm.
20. Use of a kit according to any of claims 10 to 19 in a method according to any of claims 1 to 9 and 14 to 19.
21. A kit for enhancing the imaging of one or more components in a system by magnetic resonance imaging, each component being capable of binding to a probe, comprising
- 25 - one or more biotin-labelled probes
- streptavidin-metal particle complex, and
- conjugate comprising:
 - biotin,
 - polymer, and
 - metal particles bound to said polymer.
- 30 22. A method according to any of claims 1 to 9, 14 to 19 or a kit according to any of claims 10 to 19, and 21, wherein said probe is an antibody, nucleic acid, peptide nucleic acid, polypeptide or peptide ligand.
- 35 23. A method according to any of claims 1 to 9, 14 to 19 and 22 or a kit according to any of claims 10 to 19, 21 and 22, wherein streptavidin-metal particle complex comprises one or more particles of gold, silver, iron, nickel, gadolinium, lead, uranium, caesium, platinum, palladium, rhodium, technetium, tellurium, selenium, silicon (silicium), copper, tin, rhenium, europium, aluminium, germanium, chromium, cadmium, niobium, titanium, magnesium, manganese, molybdenum, antimony, americium, lithium, and/or wolfram.
- 40 24. A method according to any of claims 1 to 9, 15 to 19 and 22 or a kit according to any of claims 10 to 19, 21 to 23, wherein said streptavidin-metal particle complex comprises one or more gold particles.
- 45 25. A method according to any of claims 1 to 9, 15 to 19 and 22 or a kit according to any of claims 10 to 19, 21 to 23, wherein said streptavidin-metal particle complex comprises one or more silver particles.
26. A method according to any of claims 1 to 9, 15 to 19 and 22 to 25 or a kit according to any of claims 10 to 19, 21 to 50 25, wherein the metal particles of said streptavidin-metal particle complex have a diameter between 0.6 to 40 nm.
27. A method according to any of claims 1 to 9, 15 to 19 and 22 to 26 or a kit according to any of claims 10 to 19, 21 to 26, wherein said streptavidin-metal particle complex comprises streptavidin and/or avidin.
- 55 28. A method according to any of claims 1 to 9, 15 to 19 and 22 to 27, or a kit according to any of claims 10 to 19, 21 to 27, wherein said streptavidin-metal particle complex and/or conjugate comprise one or more superparamagnetic particles.
29. A method according to any of claims 1 to 9, 15 to 19 and 22 to 28, or a kit according to any of claims 10 to 19 and

21 to 28, wherein said streptavidin-metal particle complex comprises one or more superparamagnetic particles, and wherein steps (d) and (e) are not performed.

30. A method or kit according to claim 28 or 29 wherein said superparamagnetic particles comprise iron oxide.

5

31. A method or kit according to claim 30 wherein the iron oxide content of a superparamagnetic particle is between 30 and 80%.

10

32. A method or kit according to any of claims 28 to 31 wherein said superparamagnetic particles have a diameter between 50 and 400nm.

33. A method according to any of claims 1 to 9, 15 to 19 and 22 to 32, or a kit according to any of claims 10 to 19, 21 to 32 wherein at least one probe is capable of binding to Human Papillomavirus.

15

34. A method or kit according to claim 33, wherein said probe is capable of binding to Human Papillomavirus coat polypeptide.

35. A method or kit according to claims 33 or 34, for detecting, diagnosing and/or monitoring the progress of a Human Papillomavirus (HPV) infection.

20

36. A kit according to claims 33 or 34, wherein at least one probe is capable of binding to a gene selected from the group consisting of HPV 16, HPV18, HPV 31, HPV 33, HPV 35, HPV 52 and HPV 58.

25

37. A method according to any of claims 1 to 9, 15 to 19 and 22 to 32, or a kit according to any of claims 10 to 19, 21 to 32, wherein said probe is capable of binding to a component listed in Table 1.

38. A method or kit according to claim 37, for detecting, diagnosing and/or monitoring the progress of or susceptibility to one or more of the disease states in humans as listed in Table 1, by detecting a polypeptide and/or nucleic acid corresponding to a component therein.

30

39. A method according to any of claims 1 to 9, 15 to 19 and 22 to 32, or a kit according to any of claims 10 to 19, 21 to 32, wherein at least one probe is capable of binding to any of HCV, HIV, HBV, HTLV, mycobacteria, or *Staphylococcus aureus*.

35

40. A method or kit according to claim 39, for detecting, diagnosing and/or monitoring the progress infections caused by one or more of one or more of HCV, HIV, HBV, HTLV, mycobacteria, or *Staphylococcus aureus*.

41. A method according to any of claims 1 to 9, 15 to 19 and 22 to 32, or a kit according to any of claims 10 to 19, 21 to 32, wherein at least one probe is capable of binding to one or more of beta-amyloids, hTAU, phosphoTAU and APOE

40

42. A method or kit according to claim 41, for use in detecting, diagnosing and/or monitoring the progress neurodegenerative diseases.

43. A method according to any of claims 1 to 9, 15 to 19 and 22 to 32, or a kit according to any of claims 10 to 19, 21 to 32 wherein at least one probe is capable of binding to one or more of ANA, Jo-1, Myeloperoxidase, RNP, Scl-70, Sm, SS-A, IgE, IgG-subclasses and circulating antibodies.

44. A method or kit according to claim 43 for use in detecting, diagnosing and/or monitoring the progress of malignant diseases, autoimmunity or allergy related diseases.

50

45. A method according to any of claims 1 to 9, 15 to 19 and 22 to 32, or a kit according to any of claims 10 to 19, 21 to 32, wherein at least one probe is capable of binding to microorganism contaminants of drinking water.

46. A method or kit according to claim 45, for environmental testing of water for bacteria.

55

47. A method according to any of claims 1 to 9, 15 to 19 and 22 to 32, or a kit according to claims 10 to 19, 21 to 32, for use in environmental testing of food components for genetically modified components, listeria and salmonella.

48. A method for staining components in cell and/or tissue sections, said staining suitable for visualisation using microscopy comprises the following steps:

5 A) incubating section with one or more biotinylated probes directed against said components,
B) incubating section with streptavidin-metal particle complex,
C) incubating section with conjugate comprising:
10 - one or more biotins,
- one or more polymers, and
- metal particles bound to said polymer, and
D) optionally incubating the section with metal enhancement reagent.

15 **Patentansprüche**

1. Verfahren für die quantitative und/oder qualitative Erfassung von einer oder mehreren Komponenten in einer Probe, wobei jede Komponente dazu fähig ist, sich an eine Sonde zu binden, umfassend Schritte in folgender Reihenfolge:

20 (a) Aufbringen einer oder mehrerer Proben auf einen festen Träger,
(b) Kontaktieren des festen Trägers mit einer oder mehreren biotingelabelten Sonden,
(c) Kontaktieren des festen Trägers mit einem Streptavidin-Metallteilchen-Komplex,
(d) Kontaktieren des festen Trägers mit Konjugat umfassend:
25 - ein oder mehrere Biotine,
- ein oder mehrere Polymere und
- Metallteilchen, die an das Polymer gebunden sind,
(e) wahlweises Kontaktieren des festen Trägers mit Metallenhancementreagens und
30 (f) Lesen des festen Trägers zum quantitativen und/oder qualitativen Erfassen der Komponente.

2. Verfahren nach Anspruch 1, wobei der Schritt (a) durch:

35 (a) Aufbringen einer oder mehrerer Sonden auf den festen Träger ersetzt wird und der Schritt (b) durch:
(b) Kontaktieren des festen Trägers mit biotingelabelter Probe ersetzt wird.

3. Verfahren nach Anspruch 1, wobei dem Schritt (a) Folgendes vorausgeht:

40 (aO) Aufbringen einer oder mehrerer Sonden auf den festen Träger.

4. Verfahren nach Anspruch 2 oder 3, wobei der feste Träger mit vorher aufgebrachter Sonde beliefert und Schritt (a) des Anspruchs 2 oder Schritt (aO) des Anspruchs 3 nicht durch den Anwender durchgeführt wird.
5. Verfahren nach einem der Ansprüche 1 bis 4, wobei das Lesen des Schritts (f) die Verwendung einer Farbtafel umfasst.
50 6. Verfahren nach einem der Ansprüche 1 bis 4, wobei das Lesen des Schritts (f) eine Verwendung eines Geräts umfasst, das für das Erfassen von Änderungen der Leitfähigkeit und/oder des Stroms über den festen Träger geeignet ist.
7. Verfahren nach einem der Ansprüche 1 bis 4, wobei das Lesen des Schritts (f) eine Verwendung eines Geräts umfasst, das für das Erfassen von Änderungen im Magnetfeld auf dem festen Träger geeignet ist.
8. Verfahren nach einem der Ansprüche 1 bis 4, wobei das Lesen des Schritts (f) eine Verwendung eines Geräts umfasst, das für das Erfassen von Änderungen in der Oberflächenplasmonresonanz auf dem festen Träger geeignet ist.
55 9. Verfahren nach einem der Ansprüche 1 bis 8, wobei das Metallenhancementreagens des Schritts (e) ein Silberen-

hancementreagens ist.

10. Kit für die quantitative und/oder qualitative Erfassung von einer oder mehreren Komponenten in einer Probe, wobei jede Komponente dazu fähig ist, sich an eine Sonde zu binden, umfassend:

5

- Streptavidin-Metallteilchen-Komplex,
- einen festen Träger und
- Konjugat umfassend:

10

- Biotin,
- Polymer und
- Metallteilchen, die an das Polymer gebunden sind.

11. Kit nach Anspruch 10, des Weiteren umfassend:

15

- eine oder mehrere Sonden.

12. Kit nach Anspruch 11, wobei die Sonden biotinyliert sind.

20

13. Kit nach einem der Ansprüche 10 bis 12, wobei der feste Träger mit einer oder mehreren Sonden vorbeladen ist.

14. Verfahren nach einem der Ansprüche 1 bis 9, oder Kit nach einem der Ansprüche 10 bis 13, wobei das Polymer eines Konjugats ein biologisch inertes Polymer ist, das dazu fähig ist, sich an ein oder mehrere Metallteilchen zu binden.

25

15. Verfahren oder Kit nach Anspruch 14, wobei ein Polymer eines von Albumin oder Dextran ist.

16. Verfahren nach einem der Ansprüche 1 bis 9, 14 oder 15 oder Kit nach einem der Ansprüche 10 bis 13, wobei das Konjugat ein oder mehrere Teilchen von Gold, Silber, Eisen, Nickel, Gadolin, Blei, Uran, Cäsium, Platin, Rhodium, Technetium, Tellur, Selen, Silicium, Silicium, Kupfer, Zinn, Rhenium, Europium, Aluminium, Germanium, Chrom, Cadmium, Niob, Titan, Magnesium, Mangan, Molybdän, Antimon, Americium, Lithium und/oder Wolfram umfasst.

30

17. Verfahren nach einem der Ansprüche 1 bis 9, 14 oder 15 oder Kit nach einem der Ansprüche 10 bis 13, wobei das Konjugat ein oder mehrere Goldteilchen umfasst.

35

18. Verfahren nach einem der Ansprüche 1 bis 9, 14 oder 15 oder Kit nach einem der Ansprüche 10 bis 13, wobei das Konjugat ein oder mehrere Silberteilchen umfasst

40

19. Verfahren nach einem der Ansprüche 1 bis 9, 14 bis 18 oder Kit nach einem der Ansprüche 10 bis 18, wobei die Metallteilchen des Konjugats einen Durchmesser zwischen 0,6 und 40 nm aufweisen.

20. Verwendung eines Kits nach einem der Ansprüche 10 bis 19 bei einem Verfahren nach einem der Ansprüche 1 bis 9 und 14 bis 19.

45

21. Kit für das Verbessern der Bilderkennung einer oder mehrerer Komponenten in einem System durch Magnetresonanzbilderkennung, wobei jede Komponente dazu fähig ist, sich an eine Sonde zu binden, umfassend

50

- eine oder mehrere biotingelabelte Sonden,
- Streptavidin-Metallteilchen-Komplex und

- Konjugat umfassend:

- Biotin,
- Polymer und
- Metallteilchen, die an das Polymer gebunden sind.

55

22. Verfahren nach einem der Ansprüche 1 bis 9, 14 bis 19 oder Kit nach einem der Ansprüche 10 bis 19 und 21, wobei die Sonde ein Antikörper, eine Nucleinsäure, eine Peptidnucleinsäure, ein Polypeptid oder Peptidligand ist.

23. Verfahren nach einem der Ansprüche 1 bis 9, 14 bis 19 und 22 oder Kit nach einem der Ansprüche 10 bis 19, 21 und 22, wobei der Streptavidin-Metallteilchen-Komplex ein oder mehrere Teilchen von Gold, Silber, Eisen, Nickel, Gadolin, Blei, Uran, Cäsium, Platin, Palladium, Rhodium, Technetium, Tellur, Selen, Silicium (Silicium), Kupfer, Zinn, Rhenium, Europium, Aluminium, Germanium, Chrom, Cadmium, Niob, Titan, Magnesium, Mangan, Molybdän, Antimon, Americium, Lithium und/oder Wolfram umfasst.

5

24. Verfahren nach einem der Ansprüche 1 bis 9, 15 bis 19 und 22 oder Kit nach einem der Ansprüche 10 bis 19, 21, 23, wobei der Streptavidin-Metallteilchen-Komplex in oder mehrere Goldteilchen umfasst.

10

25. Verfahren nach einem der Ansprüche 1 bis 9, 15 bis 19 und 22 oder Kit nach einem der Ansprüche 10 bis 19, 21 bis 23, wobei der Streptavidin-Metallteilchen-Komplex ein oder mehrere Silberteilchen umfasst

15

26. Verfahren nach einem der Ansprüche 1 bis 9, 15 bis 19 und 22 bis 25, oder Kit nach einem der Ansprüche 10 bis 19, 21 bis 25, wobei die Metallteilchen des Streptavidin-Metallteilchen-Komplexes einen Durchmesser zwischen 0,6 und 40 nm aufweisen.

27. Verfahren nach einem der Ansprüche 1 bis 9, 15 bis 19 und 22 bis 26, oder Kit nach einem der Ansprüche 10 bis 19, 21 bis 26, wobei der Streptavidin-Metallteilchen-Komplex Streptavidin und/oder Avidin umfasst.

20

28. Verfahren nach einem der Ansprüche 1 bis 9, 15 bis 19 und 22 bis 27, oder Kit nach einem der Ansprüche 10 bis 19, 21 bis 27, wobei der Streptavidin-Metallteilchen-Komplex und/oder das Konjugat ein oder mehrere superparamagnetische Teilchen umfasst.

25

29. Verfahren nach einem der Ansprüche 1 bis 9, 15 bis 19 und 22 bis 28 oder Kit nach einem der Ansprüche 10 bis 19 und 21 bis 28, wobei der Streptavidin-Metallteilchen-Komplex ein oder mehrere superparamagnetische Teilchen umfasst und wobei die Schritte (d) und (e) nicht durchgeführt werden.

30

30. Verfahren oder Kit nach Anspruch 28 oder 29, wobei die superparamagnetischen Teilchen Eisenoxid umfassen.

30

31. Verfahren oder Kit nach Anspruch 30, wobei der Eisenoxidgehalt eines superparamagnetischen Teilchens zwischen 30 und 80 % liegt.

35

32. Verfahren oder Kit nach einem der Ansprüche 28 bis 31, wobei die superparamagnetischen Teilchen einen Durchmesser zwischen 50 und 400 nm aufweisen.

33. Verfahren nach einem der Ansprüche 1 bis 9, 15 bis 19 und 22 bis 32 oder Kit nach einem der Ansprüche 10 bis 19, 21 bis 32, wobei mindestens eine Sonde dazu fähig ist, sich an menschliches Papillomvirus zu binden.

40

34. Verfahren oder Kit nach Anspruch 33, wobei die Sonde dazu fähig ist, sich an Beschichtungspolypeptid des menschlichen Papillomvirus zu binden.

35

35. Verfahren oder Kit nach den Ansprüchen 33 oder 34 für die Erfassung, Diagnose und/oder Überwachung des Fortschreitens einer Infektion durch ein menschliches Papillomvirus (HPV).

45

36. Kit nach den Ansprüchen 33 oder 34, wobei mindestens eine Sonde dazu fähig ist, sich an ein Gen ausgewählt aus der Gruppe bestehend aus HPV 16, HPV 18, HPV 31, HPV 33, HPV 35, HPV 52 und HPV 58 zu binden.

37. Verfahren nach einem der Ansprüche 1 bis 9, 15 bis 19 und 22 bis 32, oder Kit nach einem der Ansprüche 10 bis 19, 21 bis 32, wobei die Sonde dazu fähig ist, sich an eine in Tabelle 1 aufgelistete Komponente zu binden.

50

38. Verfahren oder Kit nach Anspruch 37 für die Erfassung, Diagnose und/oder Überwachung des Fortschreitens einer oder mehrerer oder der Anfälligkeit für eine oder mehrere der Krankheitszustände beim Menschen, wie in Tabelle 1 aufgelistet, durch Erfassen eines Polypeptids und/oder einer Nucleinsäure, das bzw. die einer Komponente darin entspricht.

55

39. Verfahren nach einem der Ansprüche 1 bis 9, 15 bis 19 und 22 bis 32 oder Kit nach einem der Ansprüche 10 bis 19, 21 bis 32, wobei mindestens eine Sonde dazu fähig ist, sich an eines von HCV, HIV, HBV, HTLV, Mykobakterien oder *Staphylococcus aureus* zu binden.

40. Verfahren oder Kit nach Anspruch 39 für die Erfassung, Diagnose und/oder Überwachung des Fortschreitens von Infektionen, die durch eines oder mehrere von HCV, HIV, HBV, HTLV, Mykobakterien oder *Staphylococcus aureus* hervorgerufen werden.

5 41. Verfahren nach einem der Ansprüche 1 bis 9, 15 bis 19 und 22 bis 32 oder Kit nach einem der Ansprüche 10 bis 19, 21 bis 32, wobei mindestens eine Sonde dazu fähig ist, sich an eines oder mehrere von Beta-Amyloiden, hTAU, PhosphoTAU und APOE zu binden.

10 42. Verfahren oder Kit nach Anspruch 41 zur Verwendung für die Erfassung, Diagnose und/oder Überwachung des Fortschreitens neurodegenerativer Krankheiten.

15 43. Verfahren nach einem der Ansprüche 1 bis 9, 15 bis 19 und 22 bis 32 oder Kit nach einem der Ansprüche 10 bis 19, 21 bis 32, wobei mindestens eine Sonde dazu fähig ist, sich an eines oder mehrere von ANA, Jo-1, Myeloperoxidase, RNP, Scl-70, Sm, SS-A, IgE, IgG-Subklassen und zirkulierenden Antikörpern zu binden.

15 44. Verfahren oder Kit nach Anspruch 43 zur Verwendung für die Erfassung, Diagnose und/oder Überwachung des Fortschreitens maligner Krankheiten, Autoimmun- oder mit Allergie verbundener Krankheiten.

20 45. Verfahren nach einem der Ansprüche 1 bis 9, 15 bis 19 und 22 bis 32 oder Kit nach einem der Ansprüche 10 bis 19, 21 bis 32, wobei mindestens eine Sonde dazu fähig ist, sich an Trinkwasser verschmutzende Mikroorganismen zu binden.

25 46. Verfahren oder Kit nach Anspruch 45 für die Umweltprüfung von Wasser auf Bakterien.

25 47. Verfahren nach einem der Ansprüche 1 bis 9, 15 bis 19 und 22 bis 32 oder Kit nach einem der Ansprüche 10 bis 19, 21 bis 32 zur Verwendung für die Umweltprüfung von Nahrungsmittelbestandteilen auf genmodifizierte Komponenten, Listeria und Salmonella hin.

30 48. Verfahren für das Färben von Komponenten in Zell- und/oder Gewebeabschnitten, wobei das Färben für das Sichtbarmachen mit Hilfe von Mikroskopie geeignet ist, umfassend die folgenden Schritte:

35 A) Inkubieren des Abschnitts mit einer oder mehreren biotinylierten Sonden, die gegen die Komponenten gerichtet sind,

B) Inkubieren des Abschnitts mit Streptavidin-Metallteilchen-Komplex,

C) Inkubieren des Abschnitts mit Konjugat umfassend:

40 - ein oder mehrere Biotine,

- ein oder mehrere Polymere und

- Metallteilchen, die an das Polymer gebunden sind und

40 D) wahlweise Inkubieren des Abschnitts mit Metallenhancementreagens.

Revendications

45 1. Procédé de détection quantitative et/ou qualitative d'un ou de plusieurs composants dans un échantillon, chaque composant étant capable de se lier à une sonde, qui comprend les étapes dans l'ordre suivant :

50 (a) l'application d'un ou de plusieurs échantillons sur un support solide,

(b) la mise en contact du support solide avec une ou plusieurs sondes marquées à la biotine,

(c) la mise en contact du support solide avec un complexe de streptavidine-particules de métal,

(d) la mise en contact du support solide avec un conjugué comprenant :

55 - une ou plusieurs biotines,

- un ou plusieurs polymères, et

- des particules de métal liées au dit polymère,

(e) facultativement la mise en contact du support solide avec un réactif d'exaltation du métal, et

(f) la lecture du support solide pour détecter quantitativement et/ou qualitativement ledit composant.

2. Procédé selon la revendication 1, dans lequel l'étape (a) est remplacée par:

5 (a) l'application d'une ou de plusieurs sondes sur un support solide,
et l'étape (b) est remplacée par :
(b) la mise en contact du support solide avec un échantillon marqué à la biotine.

10 3. Procédé selon la revendication 1, dans lequel l'étape (a) est précédée par :

(a0) l'application d'une ou de plusieurs sondes sur un support solide.

15 4. Procédé selon les revendications 2 ou 3, dans lequel le support solide est fourni avec une sonde pré-appliquée, et
l'étape (a) de la revendication 2 ou l'étape (a0) de la revendication 3 n'est pas réalisée par l'utilisateur.

15 5. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel la lecture de l'étape (f) comprend l'utilisation
d'un nuancier.

20 6. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel la lecture de l'étape (f) comprend une utilisation
d'un dispositif adapté pour la détection des modifications dans la conductance et/ou dans le courant dans le support
solide.

25 7. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel la lecture de l'étape (f) comprend une utilisation
d'un dispositif adapté pour la détection des modifications dans le champ magnétique sur le support solide.

30 8. Procédé selon l'une quelconque des revendications 1 à 4, dans lequel la lecture de l'étape (f) comprend une utilisation
d'un dispositif adapté pour la détection des modifications dans la résonnance plasmonique de surface sur le support
solide.

30 9. Procédé selon l'une quelconque des revendications 1 à 8, dans lequel le réactif d'exaltation du métal de l'étape (e)
est un réactif d'exaltation de l'argent.

35 10. Kit de détection quantitative et/ou qualitative d'un ou de plusieurs composants dans un échantillon, chaque com-
posant étant capable de se lier à une sonde, qui comprend :

- un complexe streptavidine - particules de métal,
- un support solide, et
- un conjugué, comprenant :

40 - de la biotine,
- un polymère, et
- des particules de métal liées au dit polymère.

45 11. Kit selon la revendication 10 comprenant en outre :

- une ou plusieurs sondes.

12. Kit selon la revendication 11, dans lequel lesdites sondes sont biotinylées.

50 13. Kit selon l'une quelconque des revendications 10 à 12, dans lequel ledit support est pré-chargé d'une ou de plusieurs
sondes.

55 14. Procédé selon l'une quelconque des revendications 1 à 9, ou un kit selon l'une quelconque des revendications 10
à 13, dans lequel le polymère d'un conjugué est un polymère biologiquement inerte, capable de se lier à une ou
plusieurs particules de métal.

15. Procédé ou kit selon la revendication 14, dans lequel un polymère est l'un quelconque de l'albumine ou du dextrane.

16. Procédé selon l'une quelconque des revendications 1 à 9, 14 ou 15, ou un kit selon l'une quelconque des revendications 10 à 13, dans lequel le conjugué comprend une ou plusieurs particules d'or, d'argent, de fer, de nickel, de gadolinium, de plomb, d'uranium, de césum, de platine, de rhodium, de technétium, de tellurium, de sélénium, de silicium, de silicium, de cuivre, d'étain, de rhénium, d'europium, d'aluminium, de germanium, de chrome, de cadmium, de niobium, de titane, de magnésium, de manganèse, de molybdène, d'antimoine, d'américium, de lithium, et/ou de tungstène.

17. Procédé selon l'une quelconque des revendications 1 à 9, 14 ou 15, ou un kit selon l'une quelconque des revendications 10 à 13, dans lequel le conjugué comprend une ou plusieurs particules d'or.

18. Procédé selon l'une quelconque des revendications 1 à 9, 14 ou 15, ou un kit selon l'une quelconque des revendications 10 à 13; dans lequel un conjugué comprend une ou plusieurs particules d'argent.

19. Procédé selon l'une quelconque des revendications 1 à 9, 14 à 18, ou un kit selon l'une quelconque des revendications 10 à 18, dans lequel les particules de métal du conjugué ont un diamètre compris entre 0,6 et 40 nm.

20. Utilisation d'un kit selon l'une quelconque des revendications 10 à 19, dans un procédé selon l'une quelconque des revendications 1 à 9 et 14 à 19.

21. Kit d'amélioration de l'imagerie d'un ou de plusieurs composants dans un système par imagerie par résonance magnétique, chaque composant étant capable de se lier à une sonde, qui comprend :

- une ou plusieurs sondes marquées à la biotine
- un complexe streptavidine - particules de métal, et
- un conjugué, comprenant :
 - de la biotine,
 - un polymère, et
 - des particules de métal liées au dit polymère.

22. Procédé selon l'une quelconque des revendications 1 à 9, 14 à 19, ou un kit selon l'une quelconque des revendications 10 à 19, et 21, dans lequel ladite sonde est un anticorps, un acide nucléique, un acide nucléique peptidique, un ligand polypeptidique ou peptidique.

23. Procédé selon l'une quelconque des revendications 1 à 9, 14 à 19 et 22 ou un kit selon l'une quelconque des revendications 10 à 19, 21 et 22, dans lequel le complexe de streptavidine - particules de métal comprend une ou plusieurs particules d'or, d'argent, de fer, de nickel, de gadolinium, de plomb, d'uranium, de césum, de platine, de palladium, de rhodium, de technétium, de tellurium, de sélénium, de silicium (silicium), de cuivre, d'étain, de rhénium, d'europium, d'aluminium, de germanium, de chrome, de cadmium, de niobium, de titane, de magnésium, de manganèse, de molybdène, d'antimoine, d'américium, de lithium, et/ou de tungstène.

24. Procédé selon l'une quelconque des revendications 1 à 9, 15 à 19 et 22 ou un kit selon l'une quelconque des revendications 10 à 19, 21 à 23, dans lequel ledit complexe de streptavidine - particules de métal comprend une ou plusieurs particules d'or.

25. Procédé selon l'une quelconque des revendications 1 à 9, 15 à 19 et 22 ou un kit selon l'une quelconque des revendications 10 à 19, 21 à 23, dans lequel ledit complexe de streptavidine - particules de métal comprend une ou plusieurs particules d'argent.

26. Procédé selon l'une quelconque des revendications 1 à 9, 15 à 19 et 22 à 25 ou un kit selon l'une quelconque des revendications 10 à 19, 21 à 25, dans lequel les particules de métal dudit complexe streptavidine - particules de métal ont un diamètre compris entre 0,6 et 40 nm.

27. Procédé selon l'une quelconque des revendications 1 à 9, 15 à 19 et 22 à 26 ou un kit selon l'une quelconque des revendications 10 à 19, 21 à 26, dans lequel ledit complexe de streptavidine - particules de métal comprend de la streptavidine et/ou de l'avidine.

28. Procédé selon l'une quelconque des revendications 1 à 9, 15 à 19 et 22 à 27, ou un kit selon l'une quelconque des

revendications 10 à 19, 21 à 27, dans lequel ledit complexe de streptavidine - particules de métal et/ou ledit conjugué comprennent une ou plusieurs particules super paramagnétiques.

29. Procédé selon l'une quelconque des revendications 1 à 9, 15 à 19 et 22 à 28, ou un kit selon l'une quelconque des 5 revendications 10 à 19 et 21 à 28, dans lequel ledit complexe de streptavidine - particules de métal comprend une ou plusieurs particules super paramagnétiques, et, dans lequel les étapes (d) et (e) ne sont pas réalisées.

30. Procédé ou kit selon la revendication 28 ou 29, dans lequel lesdites particules super paramagnétiques comprennent 10 de l'oxyde de fer.

31. Procédé ou kit selon la revendication 30, dans lequel la teneur en oxyde de fer d'une particule super paramagnétique est comprise entre 30 et 80%.

32. Procédé ou kit selon l'une quelconque des revendications 28 à 31, dans lequel lesdites particules super paramagnétiques ont un diamètre compris entre 50 et 400 nm.

33. Procédé selon l'une quelconque des revendications 1 à 9, 15 à 19 et 22 à 32, ou un kit selon l'une quelconque des revendications 10 à 19, 21 à 32 dans lequel au moins une sonde est capable de liaison au papillomavirus humain.

34. Procédé ou kit selon la revendication 33, dans lequel ladite sonde est capable de liaison au polypeptide d'enveloppe 20 du papillomavirus humain.

35. Procédé ou kit selon les revendications 33 ou 34, pour la détection, le diagnostic et/ou la surveillance de l'évolution 25 d'une infection à papillomavirus humain (HPV).

36. Kit selon les revendications 33 ou 34, dans lequel au moins une sonde est capable de se lier à un gène choisi dans le groupe constitué par le HPV 16, le HPV18, le HPV 31, le HPV 33, le HPV 35, le HPV 52 et le HPV 58.

37. Procédé selon l'une quelconque des revendications 1 à 9, 15 à 19 et 22 à 32, ou un kit selon l'une quelconque des 30 revendications 10 à 19, 21 à 32, dans lequel ladite sonde est capable de se lier à un composant apparaissant dans la liste du tableau 1.

38. Procédé ou kit selon la revendication 37, pour la détection, le diagnostic et/ou la surveillance de l'évolution ou de 35 la prédisposition à un ou plusieurs des états pathologiques chez des êtres humains qui apparaissent dans la liste du tableau 1, par détection d'un polypeptide et/ou d'un acide nucléique correspondant à un composant à l'intérieur de ceux-ci.

39. Procédé selon l'une quelconque des revendications 1 à 9, 15 à 19 et 22 à 32, ou un kit selon l'une quelconque des revendications 10 à 19, 21 à 32, dans lequel au moins une sonde est capable de se lier à l'un quelconque du HCV, 40 du VIH, du HBV, du HTLV, des mycobactéries, ou de *Staphylococcus aureus*.

40. Procédé ou kit selon la revendication 39, pour la détection, le diagnostic et/ou la surveillance de l'évolution d'infections causées par un ou plusieurs du HCV, du VIH, du HBV, du HTLV, des mycobactéries, ou de *Staphylococcus aureus*.

41. Procédé selon l'une quelconque des revendications 1 à 9, 15 à 19 et 22 à 32, ou un kit selon l'une quelconque des revendications 10 à 19, 21 à 32, dans lequel au moins une sonde est capable de se lier à un ou plusieurs des bêta-amyloïdes, de hTAU, de phosphoTAU et d'APOE

42. Procédé ou kit selon la revendication 41, destiné à être utilisé pour la détection, le diagnostic et/ou la surveillance 50 de l'évolution des maladies neurodégénératives.

43. Procédé selon l'une quelconque des revendications 1 à 9, 15 à 19 et 22 à 32, ou un kit selon l'une quelconque des revendications 10 à 19, 21 à 32, dans lequel au moins une sonde est capable de se lier à un ou plusieurs des ANA, Jo-1, Myéloperoxydase, RNP, Scl-70, Sm, SS-A, IgE, sous-classes des IgG et anticorps circulants.

44. Procédé ou kit selon la revendication 43 destiné à être utilisé pour la détection, le diagnostic et/ou la surveillance 55 de l'évolution de maladies malignes, de maladies liées à l'auto-immunité ou aux allergies.

45. Procédé selon l'une quelconque des revendications 1 à 9, 15 à 19 et 22 à 32, ou un kit selon l'une quelconque des revendications 10 à 19, 21 à 32, dans lequel au moins une sonde est capable de se lier à des contaminants de microorganismes de l'eau potable.

5 46. Procédé ou kit selon la revendication 45, pour le test environnemental des bactéries dans l'eau.

47. Procédé selon l'une quelconque des revendications 1 à 9, 15 à 19 et 22 à 32, ou un kit selon les revendications 10 à 19, 21 à 32, destiné à être utilisé pour tester la présence de composants génétiquement modifiés, de listeria et de salmonella dans des composants alimentaires.

10 48. Procédé de coloration de composants dans des sections cellulaires et/ou tissulaires, ladite coloration adaptée pour la visualisation en utilisant la microscopie comprend les étapes suivantes :

15 A) l'incubation de la section avec une ou plusieurs sondes biotinylées dirigées contre lesdits composants,
B) l'incubation de la section avec le complexe streptavidine - particules de métal,
C) l'incubation de la section avec le conjugué comprenant :

20 - une ou plusieurs biotines,
- un ou plusieurs polymères, et
- des particules de métal liées au dit polymère, et

25 D) facultativement l'incubation de la section avec le réactif d'exaltation du métal.

30

35

40

45

50

55

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- WO 0072018 A [0003]
- EP 1164201 A [0003] [0003] [0003]
- EP 1096024 A [0003] [0003]
- WO 01177372 A2 [0003]
- US 20010010906 A1 [0003] [0003]
- WO 0017201 A [0003]
- WO 0177372 A2 [0003]
- EP 10960245 A [0003]
- AU 8366001 [0003]
- AU 7547501 [0003]
- CA 2397280 [0003]
- WO 0196604 A [0003]
- WO 9920789 A [0003]
- US 6451980 B [0003]
- WO 02106511 A, Genisphere [0003]
- WO 0136681 A, Digene [0003]
- WO 9614314 A, DAKO [0003]
- EP 0151492 A, ENZO [0003]
- US 5691207 A [0004]
- US 20030186274 A [0004]
- US 20020000398 A [0004]

Non-patent literature cited in the description

- W.M. DANKER et al. *The Journal of Histotechnology*, 1989, vol. 12 (1), 9-13 [0004]
- KUMAR et al. Silanized nucleic acids: a general platform for DNA immobilization. *Nucleic acids res*, 2000, vol. 28, 71 [0167]